

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



94

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12Q 1/68</b>	<b>A2</b>	(11) International Publication Number: <b>WO 99/39006</b> (43) International Publication Date: <b>5 August 1999 (05.08.99)</b>
<p>(21) International Application Number: <b>PCT/US99/01964</b></p> <p>(22) International Filing Date: <b>29 January 1999 (29.01.99)</b></p> <p>(30) Priority Data: <b>60/073,263</b>      <b>30 January 1998 (30.01.98)</b>      <b>US</b></p> <p>(71) Applicant (for all designated States except US): <b>GENOPLEX, INC. [US/US]; 6840 N. Broadway, Denver, CO 80221 (US).</b></p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): <b>SIKELA, James, M. [US/US]; 6046 S. Kingston Circle, Englewood, CO 80111 (US). MESSIER, Walter [US/US]; 2418 Bowen Street, Longmont, CO 80501 (US).</b></p> <p>(74) Agents: <b>POLIZZ, Catherine, M. et al.; Morrison &amp; Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).</b></p>		<p>(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: <b>METHODS TO IDENTIFY POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES WHICH MAY BE ASSOCIATED WITH PHYSIOLOGICAL AND MEDICAL CONDITIONS</b></p> <p>(57) Abstract</p> <p>The present invention provides methods for identifying polynucleotide and polypeptide sequences in human and/or non-human primates which may be associated with a physiological condition, such as disease (including susceptibility (human) or resistance (chimpanzee) to development of AIDS). The methods employ comparison of human and non-human primate sequences using statistical methods. Sequences thus identified may be useful as host therapeutic targets and/or in screening assays.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



### CROSS-REFERENCE TO RELATED APPLICATIONS

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER  
FEDERALLY SPONSORED RESEARCH

TECHNICAL FIELD

## BACKGROUND ART

1

muscle to fat; (7) chimpanzees are more resistant to malaria; (8) chimpanzees are less susceptible to Alzheimer's disease; and (9) chimpanzees have a lower incidence of atherosclerosis. At the present time, the genes underlying the above human/chimpanzee differences are not known, nor, more importantly, are the specific changes that have evolved in these genes to provide these capabilities. Understanding the basis of these differences between humans and our close evolutionary relatives will provide useful information for developing effective treatments for related human conditions and diseases.

Classic evolution analysis, which compares mainly the anatomic features of animals, has revealed dramatic morphological and functional differences between human and non-human primates; yet, the human genome is known to share remarkable sequence similarities with that of other primates. For example, it is generally concluded that human DNA sequence is roughly 98.5% identical to chimpanzee DNA and only slightly less similar to gorilla DNA. McConkey and Goodman (1997) *TIG* 13:350-351. Given the relatively small percentage of genomic difference between humans and closely related primates, it is possible, if not likely, that a relatively small number of changes in genomic sequences may be responsible for traits of interest to human health and well-being, such as those listed above. Thus, it is desirable and feasible to identify the genes underlying these traits and to glean information from the evolved changes in the proteins they encode to develop treatments that could benefit human health and well-being. Identifying and characterizing these sequence changes is crucial in order to benefit from evolutionary solutions that have eliminated or minimized diseases or that provide unique or enhanced functions.

Recent developments in the human genome project have provided a tremendous amount of information on human gene sequences. Furthermore, the structures and activities of many human genes and their protein products have been studied either directly in human cells in culture or in several animal model systems, such as the nematode, fruit fly, zebrafish and mouse. These model systems have great advantages in being relatively simple, easy to manipulate, and having short generation times. Because the basic structures and biological activities of many important genes have been conserved throughout evolution, homologous genes can be identified in many species by comparing macromolecule sequences. Information obtained from lower species on important gene

Although comparison of homologous genes or proteins between human and a lower model organism may provide useful information with respect to evolutionarily conserved molecular sequences and functional features, this approach is of limited use in identifying genes whose sequences have changed due to natural selection. With the advent of the development of sophisticated algorithms and analytical methods, much more information can be teased out of DNA sequence changes. The most powerful of these methods, “ $K_A/K_S$ ” involves pairwise comparisons between aligned protein-coding nucleotide sequences of the ratios of

(where nonsynonymous means substitutions that change the encoded amino acid and synonymous means substitutions that do not change the encoded amino acid). “ $K_A/K_S$ -type methods” includes this and similar methods. These methods have been used to demonstrate the occurrence of Darwinian molecular-level positive selection, resulting in amino acid differences in homologous proteins. Several groups have used such methods to document that a particular protein has evolved more rapidly than the neutral substitution rate, and thus supports the existence of Darwinian molecular-level positive selection. For example, McDonald and Kreitman (1991) *Nature* 351:652-654 propose a statistical test of neutral protein evolution hypothesis based on comparison of the number of amino acid replacement substitutions to synonymous substitutions in the coding region of a locus. When they apply this test to the *Adh* locus of three *Drosophila* species, they conclude that it shows instead that the locus has undergone adaptive fixation of selectively advantageous mutations and that selective fixation of adaptive mutations may be a viable alternative to the clocklike accumulation of neutral mutations as an explanation for most protein evolution. Jenkins et

al. (1995) *Proc. R. Soc. Lond. B* 261:203-207 use the McDonald & Kreitman test to investigate whether adaptive evolution is occurring in sequences controlling transcription (non-coding sequences).

5 Nakashima et al. (1995) *Proc. Natl. Acad. Sci USA* 92:5606-5609, use the method of Miyata and Yasunaga to perform pairwise comparisons of the nucleotide sequences of ten PLA2 isozyme genes from two snake species; this method involves comparing the number of nucleotide substitutions per site for the noncoding regions including introns ( $K_N$ ) and the  $K_A$  and  $K_S$ . They conclude that the protein coding regions have been evolving at much higher rates than the noncoding regions including introns. The highly accelerated  
10 substitution rate is responsible for Darwinian molecular-level evolution of PLA2 isozyme genes to produce new physiological activities that must have provided strong selective advantage for catching prey or for defense against predators. Endo et al. (1996) *Mol. Biol. Evol.* 13(5):685-690 use the method of Nei and Gojobori, wherein  $d_N$  is the number of nonsynonymous substitutions and  $d_S$  is the number of synonymous substitutions, for the  
15 purpose of identifying candidate genes on which positive selection operates. Metz and Palumbi (1996) *Mol. Biol. Evol.* 13(2):397-406 use the McDonald & Kreitman test as well as a method attributed to Nei and Gojobori, Nei and Jin, and Kumar, Tamura, and Nei; examining the average proportions of  $P_n$ , the replacement substitutions per replacement site, and  $P_s$ , the silent substitutions per silent site, to look for evidence of positive selection on  
20 bindin genes in sea urchins to investigate whether they have rapidly evolved as a prelude to species formation. Goodwin et al. (1996) *Mol. Biol. Evol.* 13(2):346-358 uses similar methods to examine the evolution of a particular murine gene family and conclude that the methods provide important fundamental insights into how selection drives genetic divergence in an experimentally manipulatable system. Edwards et al. (1995) use  
25 degenerate primers to pull out *MHC* loci from various species of birds and an alligator species, which are then analyzed by the Nei and Gojobori methods ( $d_N$ :  $d_S$  ratios) to extend *MHC* studies to nonmammalian vertebrates. Whitfield et al. (1993) *Nature* 364:713-715 use  $K_A/K_S$  analysis to look for directional selection in the regions flanking a conserved region in the *SRY* gene (that determines male sex). They suggest that the rapid evolution of  
30 *SRY* could be a significant cause of reproductive isolation, leading to new species. Wettsetin et al. (1996) *Mol. Biol. Evol.* 13(1):56-66 apply the MEGA program of Kumar,

Tamura and Nei and phylogenetic analysis to investigate the diversification of *MHC* class I genes in squirrels and related rodents. Parham and Ohta (1996) *Science* 272:67-74 state that a population biology approach, including tests for selection as well as for gene conversion and neutral drift are required to analyze the generation and maintenance of human *MHC* class I polymorphism. Hughes (1997) *Mol. Biol. Evol.* 14(1):1-5 compared over one hundred orthologous immunoglobulin C2 domains between human and rodent, using the method of Nei and Gojobori ( $d_N$ :  $d_S$  ratios) to test the hypothesis that proteins expressed in cells of the vertebrate immune system evolve unusually rapidly. Swanson and Vacquier (1998) *Science* 281:710-712 use  $d_N$ :  $d_S$  ratios to demonstrate concerted evolution between the lysin and the egg receptor for lysin and discuss the role of such concerted evolution in forming new species (speciation).

Due to the distant evolutionary relationships between humans and these lower animals, the adaptively valuable genetic changes fixed by natural selection are often masked by the accumulation of neutral, random mutations over time. Moreover, some proteins evolve in an episodic manner; such episodic changes could be masked, leading to inconclusive results, if the two genomes compared are not close enough. Messier and Stewart (1997) *Nature* 385:151-154. In fact, studies have shown that the occurrence of adaptive selection in protein evolution is often underestimated when predominantly distantly related sequences are compared. Endo *et al.* (1996) *Mol. Biol. Evol.* 37:441-456; Messier and Stewart (1997) *Nature* 385:151-154.

Molecular evolution studies within the primate family have been reported, but these mainly focus on the comparison of a small number of known individual genes and gene products to assess the rates and patterns of molecular changes and to explore the evolutionary mechanisms responsible for such changes. See generally, Li, *Molecular Evolution*, Sinauer Associates, Sunderland, MA, 1997. Furthermore, sequence comparison data are used for phylogenetic analysis, wherein the evolution history of primates is reconstructed based on the relative extent of sequence similarities among examined molecules from different primates. For example, the DNA and amino acid sequence data for the enzyme lysozyme from different primates were used to study protein evolution in primates and the occurrence of adaptive selection within specific lineages. Malcolm *et al.* (1990) *Nature* 345:86-89; Messier and Stewart (1997). Other genes that have been subject

to molecular evolution studies in primates include hemoglobin, cytochrome c oxidase, and major histocompatibility complex (*MHC*). Nei and Hughes in: *Evolution at the Molecular Level*, Sinauer Associates, Sunderland, MA 222-247, 1991; Lienert and Parham (1996) *Immunol. Cell Biol.* 74:349-356; Wu *et al.* (1997) *J. Mol. Evol.* 44:477-491. Many non-coding sequences have also been used in molecular phylogenetic analysis of primates. Li, *Molecular Evolution*, Sinauer Associates, Sunderland, MA 1997. For example, the genetic distances among primate lineages were estimated from orthologous non-coding nucleotide sequences of beta-type globin loci and their flanking regions, and the evolution tree constructed for the nucleotide sequence orthologues depicted a branching pattern that is largely congruent with the picture from phylogenetic analyses of morphological characters. Goodman *et al.* (1990) *J. Mol. Evol.* 30:260-266.

Zhou and Li (1996) *Mol. Biol. Evol.* 13(6):780-783 applied  $K_A/K_S$  analysis to primate genes. It had previously been reported that gene conversion events likely have occurred in introns 2 and 4 between the red and green retinal pigment genes during human evolution. However, intron 4 sequences of the red and green retinal pigment genes from one European human were completely identical, suggesting a recent gene conversion event. In order to determine if the gene conversion event occurred in that individual, or a common ancestor of Europeans, or an even earlier hominid ancestor, the authors sequenced intron 4 of the red and green pigment gene from a male Asian human, a male chimpanzee, and a male baboon, and applied  $K_A/K_S$  analysis. They observed that the divergence between the two genes is significantly lower in intron 4 than in surrounding exons, suggesting that strong natural selection has acted against sequence homogenization.

Wolinsky *et al.* (1996) *Science* 272:537-542 used comparisons of nonsynonymous to synonymous base substitutions to demonstrate that the HIV virus itself (*i.e.*, not the host species) is subject to adaptive evolution within individual human patients. Their goal was simply to document the occurrence of positive selection in a short time frame (that of a human patient's course of disease). Niewiesk and Bangham (1996) *J Mol Evol* 42:452-458 used the  $D_n/D_s$  approach to ask a related question about the HTLV-I virus, *i.e.*, what are the selective forces acting on the virus itself. Perhaps because of an insufficient sample size, they were unable to resolve the nature of the selective forces. In both of these cases, although  $K_A/K_S$ -type methods were used in relation to a human virus, no attempt was made

to use these methods for therapeutic goals (as in the present application), but rather to pursue narrow academic goals.

As can be seen from the papers cited above, analytical methods of molecular evolution to identify rapidly evolving genes ( $K_A/K_S$ -type methods) can be applied to achieve many different purposes, most commonly to confirm the existence of Darwinian molecular-level positive selection, but also to assess the frequency of Darwinian molecular-level positive selection, to understand phylogenetic relationships, to elucidate mechanisms by which new species are formed, or to establish single or multiple origin for specific gene polymorphisms. What is clear is from the papers cited above and others in the literature is that none of the authors applied  $K_A/K_S$ -type methods to identify evolutionary solutions, specific evolved changes, that could be mimicked or used in the development of treatments to prevent or cure human conditions or diseases or to modulate unique or enhanced human functions. They have not used  $K_A/K_S$  type analysis as a systematic tool for identifying human or non-human primate genes that contain evolutionarily significant sequence changes and exploiting such genes and the identified changes in the development of treatments for human conditions or diseases.

The identification of human genes that have evolved to confer unique or enhanced human functions compared to homologous chimpanzee genes could be applied to developing agents to modulate these unique human functions or to restore function when the gene is defective. The identification of the underlying chimpanzee (or other non-human primate) genes and the specific nucleotide changes that have evolved, and the further characterization of the physical and biochemical changes in the proteins encoded by these evolved genes, could provide valuable information, for example, on what determines susceptibility and resistance to infectious diseases, such as AIDS, what determines susceptibility or resistance to the development of certain cancers, what determines susceptibility or resistance to acne, how hair growth can be controlled, and how to control the formation of muscle *versus* fat. This valuable information could be applied to developing agents that cause the human proteins to behave more like their chimpanzee homologues.

All references cited herein are hereby incorporated by reference in their entirety.

### DISCLOSURE OF THE INVENTION

The present invention provides methods for identifying polynucleotide and polypeptide sequences having evolutionarily significant changes, which are associated with physiological conditions, including medical conditions. The invention applies comparative  
5 primate genomics to identify specific gene changes which may be associated with, and thus responsible for, physiological conditions, such as medically or commercially relevant evolved traits, and using the information obtained from these evolved genes to develop human treatments. The non-human primate sequences employed in the methods described herein may be any non-human primate, and is preferably a member of the hominoid group,  
10 more preferably a chimpanzee, bonobo, gorilla and/or orangutan, and most preferably a chimpanzee.

In one preferred embodiment, a non-human primate polynucleotide or polypeptide has undergone natural selection that resulted in a positive evolutionarily significant change (i.e., the non-human primate polynucleotide or polypeptide has a positive attribute not  
15 present in humans). In this embodiment the positively selected polynucleotide or polypeptide may be associated with susceptibility or resistance to certain diseases or with other commercially relevant traits. Examples of this embodiment include, but are not limited to, polynucleotides and polypeptides that are positively selected in non-human primates, preferably chimpanzees, that may be associated with susceptibility or resistance  
20 to infectious diseases and cancer. An example of a commercially relevant trait may include aesthetic traits such as hair growth, muscle mass, susceptibility or resistance to acne. An example of this embodiment includes polynucleotides and polypeptides associated with the susceptibility or resistance to HIV dissemination, propagation and/or development of AIDS. The present invention can thus be useful in gaining insight into the molecular  
25 mechanisms that underlie resistance to HIV dissemination, propagation and/or development of AIDS, providing information that can also be useful in discovering and/or designing agents such as drugs that prevent and/or delay development of AIDS. Specific genes that have been positively selected in chimpanzees that may relate to AIDS or other infectious diseases are ICAM-1, ICAM-2, ICAM-3 and MIP-1- $\alpha$ . 17- $\beta$ -hydroxysteroid  
30 dehydrogenase Type IV is a specific gene has been positively selected in chimpanzees that may relate to cancer.



In another preferred embodiment, a human polynucleotide or polypeptide has undergone natural selection that resulted in a positive evolutionarily significant change (i.e., the human polynucleotide or polypeptide has a positive attribute not present in non-human primates). One example of this embodiment is that the polynucleotide or polypeptide may be associated with unique or enhanced functional capabilities of the human brain compared to non-human primates. Another is the longer life-span of humans compared to non-human primates. The present invention can thus be useful in gaining insight into the molecular mechanisms that underlie unique or enhanced human functions, providing information which can also be useful in designing agents such as drugs that modulate such unique or enhanced human functions, and in designing treatment of diseases or conditions related to humans. As an example, the present invention can thus be useful in gaining insight into the molecular mechanisms that underlie human cognitive function, providing information which can also be useful in designing agents such as drugs that enhance human brain function, and in designing treatment of diseases related to human brain. A specific example of a human gene that has positive evolutionarily significant changes when compared to non-human primates is a tyrosine kinase gene, KIAA 641.

Accordingly, in one aspect, the invention provides methods for identifying a polynucleotide sequence encoding a polypeptide, wherein said polypeptide may be associated with a physiological condition (such as a medically or commercially relevant positive evolutionarily significant change). The positive evolutionarily significant change can be found in humans or in non-human primates.

In one aspect of the invention, methods are provided for identifying a non-human polynucleotide sequence encoding a polypeptide, wherein said polypeptide may be associated with a physiological condition in the non-human primate, including but not limited to those physiological conditions listed (and throughout the specification), such as susceptibility or resistance to the development of a medically relevant disease state, such as an infectious disease (including viral disease, such as AIDS) or cancer. In some embodiments, methods are provided that comprise the steps of a) comparing non-human primate, preferably a chimpanzee, protein-coding polynucleotide sequences to protein-coding polynucleotide sequences of a human, wherein said human does not have the physiological condition; and b) selecting a non-human polynucleotide sequence that

contains a nucleotide change as compared to corresponding sequence of the human, wherein said change is evolutionarily significant. In some embodiments, the non-human protein-coding sequences correspond to cDNA. In some embodiments, the sequences compared are from brain. Methods used to assess the nucleotide change, and the nature(s) of the nucleotide change, are described herein, and apply to any and all embodiments. In these methods (as in other like methods described herein), the non-human protein coding sequence (and/or the polypeptide encoded therein) may be associated with development and/or maintenance of a physiological trait.

For any embodiment of this invention, the physiological condition may be any physiological condition, including those listed herein, such as, for example, disease (including susceptibility or resistance to disease) such as cancer, infectious disease (including viral diseases such as AIDS); life span; brain function, including cognitive function.

In one aspect of the invention, methods are provided for identifying a polynucleotide sequence encoding a human polypeptide, wherein said polypeptide may be associated with a physiological condition that is present in human(s), comprising the steps of: a) comparing human protein-coding polynucleotide sequences to protein-coding polynucleotide sequences of a non-human primate, wherein the non-human primate does not have the physiological condition; and b) selecting a human polynucleotide sequence that contains a nucleotide change as compared to corresponding sequence of the non-human primate, wherein said change is evolutionarily significant. In some embodiments, the human protein coding sequence (and/or the polypeptide encoded therein) may be associated with development and/or maintenance of a physiological condition. In some embodiments, the human protein-coding sequences correspond to cDNA. In some embodiments, the sequences compared are from brain. In some embodiments, the physiological condition is life span. In other embodiments, the physiological condition is a brain function. In other embodiments, the brain function is cognitive function. Methods used to assess the nucleotide change, and the nature(s) of the nucleotide change, are described herein, and apply to any and all embodiments.

In other embodiments, methods are provided that comprise the steps of: (a) comparing human protein-coding nucleotide sequences to protein-coding nucleotide

sequences of a non-human primate, preferably a chimpanzee, that is resistant to a particular medically relevant disease state, wherein the human protein coding sequence is associated with development of the disease; and (b) selecting a non-human polynucleotide sequence that contains at least one nucleotide change as compared to the corresponding sequence of the human, wherein the change is evolutionarily significant. The sequences identified by these methods may be further characterized and/or analyzed to confirm that they are associated with the development of the disease state or condition. The most preferred disease states that are applicable to these methods are cancer and infectious diseases, including AIDS, hepatitis C and leprosy.

In another aspect, the invention provides methods for identifying a polynucleotide sequence encoding a polypeptide, wherein said polypeptide may be associated with resistance to development of AIDS, comprising the steps of: (a) comparing AIDS resistant non-human primate protein coding sequences to human protein coding sequences, wherein the human protein coding sequences are associated with development of AIDS; and (b) selecting an AIDS resistant non-human primate sequence that contains at least one nucleotide change as compared to the corresponding human sequence, wherein the nucleotide change is evolutionarily significant. As indicated herein, these methods can be accomplished, for example, by aligning sequences according to their sequence homology and identifying a human polynucleotide sequence that comprises at least one unique nucleotide change over the corresponding polynucleotide sequence of the non-human primate, wherein the unique nucleotide change is positively selected according to an evolutionary analysis (as described herein).

In another aspect, methods are provided for identifying an evolutionarily significant change in a human brain protein-coding polynucleotide sequence, comprising the steps of a) comparing human brain protein-coding polynucleotide sequences to corresponding sequences of a non-human primate; and b) selecting a human polynucleotide sequence that contains a nucleotide change as compared to corresponding sequence of the non-human primate, wherein said change is evolutionarily significant. In some embodiments, the human brain protein coding nucleotide sequences correspond to human brain cDNAs.

Another aspect of the invention includes methods for identifying a positively selected human evolutionarily significant change. These methods comprise the steps of: (a)

comparing human protein-coding nucleotide sequences to protein-coding nucleotide sequences of a non-human primate; and (b) selecting a human polynucleotide sequence that contains at least one (i.e., one or more) nucleotide change as compared to corresponding sequence of the non-human primate, wherein said change is evolutionarily significant. The sequences identified by this method may be further characterized and/or analyzed for their possible association with biologically or medically relevant functions unique or enhanced in humans.

Another embodiment of the present invention is a method for large scale sequence comparison between human protein-coding polynucleotide sequences and the protein-coding polynucleotide sequences from a non-human primate, e.g., chimpanzee, comprising: (a) aligning the human polynucleotide sequences with corresponding polynucleotide sequences from non-human primate according to sequence homology; and (b) identifying any nucleotide changes within the human sequences as compared to the homologous sequences from the non-human primate, wherein the changes are evolutionarily significant. In some embodiments, the protein coding sequences are from brain.

In some embodiments, a nucleotide change identified by any of the methods described herein is a non-synonymous substitution. In some embodiments, the evolutionary significance of the nucleotide change is determined according to the non-synonymous substitution rate ( $K_A$ ) of the nucleotide sequence. In some embodiments, the evolutionarily significant changes are assessed by determining the  $K_A/K_S$  ratio between the human gene and the homologous gene from non-human primate (such as chimpanzee), and preferably that ratio is at least about 0.75, more preferably greater than about 1 (unity) (i.e., at least about 1), more preferably at least about 1.25, more preferably at least about 1.50, and more preferably at least about 2.00. In other embodiments, once a positively selected gene has been identified between human and a non-human primate (such as chimpanzee), further comparisons are performed with other non-human primates to confirm whether the human or the non-human primate (such as chimpanzee) gene has undergone positive selection.

In another aspect, the invention provides methods for correlating an evolutionarily significant human nucleotide change to a physiological condition in a human (or humans), which comprise analyzing a functional effect (which includes determining the presence of a

functional effect), if any, of (the presence or absence of) a polynucleotide sequence identified by any of the methods described herein, wherein presence of a functional effect indicates a correlation between the evolutionarily significant nucleotide change and the physiological condition. Alternatively, in these methods, a functional effect (if any) may be assessed using a polypeptide sequence (or a portion of the polypeptide sequence) encoded by a nucleotide sequence identified by any of the methods described herein.

The present invention also provides comparison of the identified polypeptides by physical and biochemical methods widely used in the art to determine the structural or biochemical consequences of the evolutionarily significant changes. Physical methods are meant to include methods that are used to examine structural changes to proteins encoded by genes found to have undergone adaptive evolution. Side-by-side comparison of the three-dimensional structures of a protein (either human or non-human primate) and the evolved homologous protein (either non-human primate or human, respectively) will provide valuable information for developing treatments for related human conditions and diseases. For example, using the methods of the present invention, the chimpanzee ICAM-1 gene was identified as having positive evolutionary changes compared to human ICAM-1. In a three-dimensional model of two functional domains of the human ICAM-1 protein it can be seen that five of the six amino acids that have been changed in chimpanzees are immediately adjacent to (i.e., physically touching) amino acid residues known to be crucial for binding to the ICAM-1 counter-receptor, LFA-1; in each case, the human amino acid has been replaced by a larger amino acid in the chimpanzee ICAM-1. Such information allows insight into designing appropriate therapeutic intervention(s).

Accordingly, in another aspect, the invention provides methods for identifying a target site (which includes one or more target sites) which may be suitable for therapeutic intervention, comprising comparing a human polypeptide (or a portion of the polypeptide) encoded in a sequence identified by any of the methods described herein, with a corresponding non-human polypeptide (or a portion of the polypeptide), wherein a location of a molecular difference, if any, indicates a target site. In another aspect, the invention provides methods for identifying a target site (which includes one or more target sites) which may be suitable for therapeutic intervention, comprising comparing a non-human polypeptide (or a portion of the polypeptide) encoded in a sequence identified by any of the

methods described herein, with a corresponding human polypeptide (or a portion of the polypeptide), wherein a location of a molecular difference, such as an amino acid difference, if any, indicates a target site.

Biochemical methods are meant to include methods that are used to examine  
5 functional differences, such as binding specificity, binding strength, or optimal binding conditions, for a protein encoded by a gene that has undergone adaptive evolution. Side-by-side comparison of biochemical characteristics of a protein (either human or non-human primate) and the evolved homologous protein (either non-human primate or human, respectively) will reveal valuable information for developing treatments for related human  
10 conditions and diseases.

In another aspect, the invention provides methods of identifying an agent which may modulate a physiological condition, said method comprising contacting an agent (i.e., at least one agent to be tested) with a cell that has been transfected with a polynucleotide sequence identified by any of the methods described herein, wherein an agent is identified  
15 by its ability to modulate function of the polynucleotide sequence. In other embodiments, the invention provides methods of identifying an agent which may modulate a physiological condition, said method comprising contacting an agent (i.e., at least one agent) to be tested with a polypeptide (or a fragment of a polypeptide and/or a composition comprising a polypeptide or fragment of a polypeptide) encoded in or within a  
20 polynucleotide identified by any of the methods described herein, wherein an agent is identified by its ability to modulate function of the polypeptide. The invention also provides agents which are identified using the screening methods described herein.

In another aspect, the invention provides methods of screening agents which may modulate the activity of the human polynucleotide or polypeptide to either modulate a  
25 unique or enhanced human function or to mimic the non-human primate trait of interest, such as susceptibility or resistance to development of a disease, such as AIDS. These methods comprise contacting a cell which has been transfected with a polynucleotide sequence with an agent to be tested, and identifying agents based on their ability to modulate function of the polynucleotide or contacting a polypeptide preparation with an  
30 agent to be tested and identifying agents based upon their ability to modulate function of the polypeptide.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a phylogenetic tree for primates within the hominoid group. The branching orders are based on well-supported mitochondrial DNA phylogenies. Messier  
5 and Stewart (1997) *Nature* 385:151-154.

Figure 2 (SEQ ID NOS:1-3) is a nucleotide sequence alignment between human and chimpanzee ICAM-1 sequences (GenBank accession numbers X06990 and X86848, respectively). The amino acid translation of the chimpanzee sequence is shown below the alignment.

10 Figure 3 shows the nucleotide sequence of gorilla ICAM-1 (SEQ ID NO:4).

Figure 4 shows the nucleotide sequence of orangutan ICAM-1 (SEQ ID NO:5).

Figures 5(A)-(E) show the polypeptide sequence alignment of ICAM-1 from several primate species.

15 Figures 6(A)-(B) show the polypeptide sequence alignment of ICAM-2 from several primate species.

Figures 7(A)-(P) show the polypeptide sequence alignment of ICAM-3 from several primate species.

Figure 8 depicts a schematic representation of a procedure for comparing human/primate brain polynucleotides, selecting sequences with evolutionarily significant  
20 changes, and further characterizing the selected sequences. The diagram of Figure 8 illustrates a preferred embodiment of the invention and together with the description serves to explain the principles of the invention, along with elaboration and optional additional steps. It is understood that any human/primate polynucleotide sequence can be compared by a similar procedure and that the procedure is not limited to brain polynucleotides.

25

### DETAILED DESCRIPTION OF THE INVENTION

The present invention applies comparative genomics to identify specific gene changes which are associated with, and thus may contribute to or be responsible for, physiological conditions, such as medically or commercially relevant evolved traits. The  
30 invention comprises a comparative genomics approach to identify specific gene changes responsible for differences in functions and diseases distinguishing humans from other non-

humans, particularly primates, and most preferably chimpanzees, including the two known species, common chimpanzees and bonobos (pygmy chimpanzees). For example, chimpanzees and humans are 98.5% identical at the DNA sequence level and the present invention can identify the adaptive molecular changes underlying differences between the species in a number of areas, including unique or enhanced human cognitive abilities and chimpanzee resistance to AIDS and certain cancers. Unlike traditional genomics, which merely identifies genes, the present invention provides exact information on evolutionary solutions that eliminate disease or provide unique functions. The present invention identifies genes that have evolved to confer an evolutionary advantage and the specific evolved changes.

The present invention results from the observation that human protein-coding polynucleotides may contain sequence changes that are found in humans but not in other evolutionarily closely related species such as non-human primates, as a result of adaptive selection during evolution.

The present invention further results from the observation that the genetic information of non-human primates may contain changes that are found in a particular non-human primate but not in humans, as a result of adaptive selection during evolution. In this embodiment, a non-human primate polynucleotide or polypeptide has undergone natural selection that resulted in a positive evolutionarily significant change (i.e., the non-human primate polynucleotide or polypeptide has a positive attribute not present in humans). In this embodiment the positively selected polynucleotide or polypeptide may be associated with susceptibility or resistance to certain diseases or other commercially relevant traits. Medically relevant examples of this embodiment include, but are not limited to, polynucleotides and polypeptides that are positively selected in non-human primates, preferably chimpanzees, that may be associated with susceptibility or resistance to infectious diseases and cancer. An example of this embodiment includes polynucleotides and polypeptides associated with the susceptibility or resistance to progression from HIV infection to development of AIDS. The present invention can thus be useful in gaining insight into the molecular mechanisms that underlie resistance to progression from HIV infection to development of AIDS, providing information that can also be useful in discovering and/or designing agents such as drugs that prevent and/or delay development of



AIDS. Commercially relevant examples include, but are not limited to, polynucleotides and polypeptides that are positively selected in non-human primates that may be associated with aesthetic traits, such as hair growth, acne or muscle mass.

Positively selected human evolutionarily significant changes in polynucleotide and polypeptide sequences may be attributed to human capabilities that provide humans with competitive advantages, particularly when compared to the closest evolutionary relative, chimpanzee, such as unique or enhanced human brain functions. The present invention identifies human genes that evolved to provide unique or enhanced human cognitive abilities and the actual protein changes that confer functional differences will be quite useful in therapeutic approaches to treat cognitive deficiencies as well as cognitive enhancement for the general population.

The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology, genetics and molecular evolution, which are within the skill of the art. Such techniques are explained fully in the literature, such as: "Molecular Cloning: A Laboratory Manual", second edition (Sambrook *et al.*, 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Current Protocols in Molecular Biology" (F.M. Ausubel *et al.*, eds., 1987); "PCR: The Polymerase Chain Reaction", (Mullis *et al.*, eds., 1994); "Molecular Evolution", (Li, 1997).

#### *Definitions*

As used herein, a "polynucleotide" refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides, or analogs thereof. This term refers to the primary structure of the molecule, and thus includes double- and single-stranded DNA, as well as double- and single-stranded RNA. It also includes modified polynucleotides such as methylated and/or capped polynucleotides. The terms "polynucleotide" and "nucleotide sequence" are used interchangeably.

As used herein, a "gene" refers to a polynucleotide or portion of a polynucleotide comprising a sequence that encodes a protein. It is well understood in the art that a gene also comprises non-coding sequences, such as 5' and 3' flanking sequences (such as promoters, enhancers, repressors, and other regulatory sequences) as well as introns.

The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. These terms also include proteins that

are post-translationally modified through reactions that include glycosylation, acetylation and phosphorylation.

A "physiological condition" is a term well-understood in the art and means any condition or state that be measured and/or observed. A "physiological condition" includes, but is not limited to, a physical condition, such as degree of body fat, alopecia (baldness), acne; life-expectancy; disease states (which include susceptibility and/or resistance to diseases), such as cancer or infectious diseases. Examples of physiological conditions are provided below (see, e.g., definitions of "human medically relevant medical condition", "human commercially relevant condition", "medically relevant evolved trait", and "commercially relevant evolved trait") and throughout the specification, and it is understood that these terms and examples refer to a physiological condition. A physiological condition may be, but is not necessarily, the result of multiple factors, any of which in turn may be considered a physiological condition. A physiological condition which is "present" in a human or non-human primate occurs within a given population, and includes those physiological conditions which are unique and/or enhanced in a given population when compared to another population.

The terms "human medically relevant condition" or "human commercially relevant condition" are used herein to refer to human conditions for which medical or non-medical (respectively) intervention is desired.

The term "medically relevant evolved trait" is used herein to refer to traits that have evolved in humans or non-human primates whose analysis could provide information (e.g., physical or biochemical data) relevant to the development of a human medical treatment.

The term "commercially relevant evolved trait" is used herein to refer to traits that have evolved in humans or non-human primates whose analysis could provide information (e.g., physical or biochemical data) relevant to the development of a non-medical product or treatment for human use.

The term " $K_A/K_S$ -type methods" means methods that evaluate differences, frequently (but not always) shown as a ratio, between the number of nonsynonymous substitutions and synonymous substitutions in homologous genes (including the more rigorous methods that determine non-synonymous and synonymous sites). These methods

are designated using several systems of nomenclature, including but not limited to  $K_A/K_S$ ,  $d_N/d_S$ ,  $D_N/D_S$ .

The terms "evolutionarily significant change" or "adaptive evolutionary change" refers to one or more nucleotide or peptide sequence change(s) between two species that may be attributed to a positive selective pressure. One method for determining the presence of an evolutionarily significant change is to apply a  $K_A/K_S$ -type analytical method, such as to measure a  $K_A/K_S$  ratio. Typically, a  $K_A/K_S$  ratio at least about 0.75, more preferably at least about 1.0, more preferably at least about 1.25, more preferably at least about 1.5 and most preferably at least about 2.0 indicates the action of positive selection and is considered to be an evolutionarily significant change.

The term "positive evolutionarily significant change" means an evolutionarily significant change in a particular species that results in an adaptive change that is positive as compared to other related species. Examples of positive evolutionarily significant changes are changes that have resulted in enhanced cognitive abilities in humans and adaptive changes in chimpanzees that have resulted in the ability of the chimpanzees infected with HIV to be resistant to progression to full-blown AIDS.

The term "resistant" means that an organism, such as a chimpanzee, exhibits an ability to avoid, or diminish the extent of, a disease condition and/or development of the disease, preferably when compared to non-resistant organisms, typically humans. For example, a chimpanzee is resistant to certain impacts of HIV and other viral infections, and/or it does not develop the ultimate disease - AIDS.

The term "susceptibility" means that an organism, such as a human, fails to avoid, or diminish the extent of, a disease condition and/or development of the disease condition, preferably when compared to an organism that is known to be resistant, such as a non-human primate, such as chimpanzee. For example, a human is susceptible to certain impacts of HIV and other viral infections and/or development of the ultimate disease - AIDS.

It is understood that resistance and susceptibility vary from individual to individual, and that, for purposes of this invention, these terms also apply to a group of individuals within a species, and comparisons of resistance and susceptibility generally refer to overall, average differences between species, although intra-specific comparisons may be used.

The term "homologous" or "homologue" or "ortholog" is known and well understood in the art and refers to related sequences that share a common ancestor and is determined based on degree of sequence identity. These terms describe the relationship between a gene found in one species and the corresponding or equivalent gene in another species. For purposes of this invention homologous sequences are compared.

"Homologous sequences" or "homologues" or "orthologs" are thought, believed, or known to be functionally related. A functional relationship may be indicated in any one of a number of ways, including, but not limited to, (a) degree of sequence identity; (b) same or similar biological function. Preferably, both (a) and (b) are indicated. The degree of sequence identity may vary, but is preferably at least 50% (when using standard sequence alignment programs known in the art), more preferably at least 60%, more preferably at least about 75%, more preferably at least about 85%. Homology can be determined using software programs readily available in the art, such as those discussed in *Current Protocols in Molecular Biology* (F.M. Ausubel *et al.*, eds., 1987) Supplement 30, section 7.718, Table 7.71. Preferred alignment programs are MacVector (Oxford Molecular Ltd, Oxford, U.K.) and ALIGN Plus (Scientific and Educational Software, Pennsylvania). Another preferred alignment program is Sequencher (Gene Codes, Ann Arbor, Michigan), using default parameters.

The term "nucleotide change" refers to nucleotide substitution, deletion, and/or insertion, as is well understood in the art.

The term "human protein-coding nucleotide sequence" which is "associated with susceptibility to AIDS" as used herein refers to a human nucleotide sequence that encodes a protein that is associated with HIV dissemination (within the organism, *i.e.*, intra-organism infectivity), propagation and/or development of AIDS. Due to the extensive research in the mechanisms underlying progression from HIV infection to the development of AIDS, a number of candidate human genes are believed or known to be associated with one or more of these phenomena. A polynucleotide (including any polypeptide encoded therein) sequence associated with susceptibility to AIDS is one which is either known or implicated to play a role in HIV dissemination, replication, and/or subsequent progression to full-blown AIDS. Examples of such candidate genes are provided below.

"AIDS resistant" means that an organism, such as a chimpanzee, exhibits an ability to avoid, or diminish the extent of, the result of HIV infection (such as propagation and dissemination) and/or development of AIDS, preferably when compared to AIDS-susceptible humans.

5 "Susceptibility" to AIDS means that an organism, such as a human, fails to avoid, or diminish the extent of, the result of HIV infection (such as propagation and dissemination) and/or development of AIDS, preferably when compared to an organism that is known to be AIDS resistant, such as a non-human primate, such as chimpanzee.

The term "brain protein-coding nucleotide sequence" as used herein refers to a nucleotide sequence expressed in the brain that encodes a protein. One example of the  
10 "brain protein-coding nucleotide sequence" is a brain cDNA sequence.

As used herein, the term "brain functions unique or enhanced in humans" or "unique functional capabilities of the human brain" or "brain functional capability that is unique or enhanced in humans" refers to any brain function, either in kind or in degree, that  
15 is identified and/or observed to be enhanced in humans compared to other non-human primates. Such brain functions include, but are not limited to high capacity information processing, storage and retrieval capabilities, creativity, memory, language abilities, brain-mediated emotional response, locomotion, pain/pleasure sensation, olfaction, and temperament.

20 "Housekeeping genes" is a term well understood in the art and means those genes associated with general cell function, including but not limited to growth, division, stasis, metabolism, and/or death. "Housekeeping" genes generally perform functions found in more than one cell type. In contrast, cell-specific genes generally perform functions in a particular cell type (such as neurons) and/or class (such as neural cells).

25 The term "agent", as used herein, means a biological or chemical compound such as a simple or complex organic or inorganic molecule, a peptide, a protein or an oligonucleotide. A vast array of compounds can be synthesized, for example oligomers, such as oligopeptides and oligonucleotides, and synthetic organic and inorganic compounds based on various core structures, and these are also included in the term "agent". In  
30 addition, various natural sources can provide compounds for screening, such as plant or

animal extracts, and the like. Compounds can be tested singly or in combination with one another.

5 The term "to modulate function" of a polynucleotide or a polypeptide means that the function of the polynucleotide or polypeptide is altered when compared to not adding an agent. Modulation may occur on any level that affects function. A polynucleotide or polypeptide function may be direct or indirect, and measured directly or indirectly.

A "function of a polynucleotide" includes, but is not limited to, replication; translation; expression pattern(s). A polynucleotide function also includes functions associated with a polypeptide encoded within the polynucleotide. For example, an agent  
10 which acts on a polynucleotide and affects protein expression, conformation, folding (or other physical characteristics), binding to other moieties (such as ligands), activity (or other functional characteristics), regulation and/or other aspects of protein structure or function is considered to have modulated polynucleotide function.

A "function of a polypeptide" includes, but is not limited to, conformation, folding  
15 (or other physical characteristics), binding to other moieties (such as ligands), activity (or other functional characteristics), and/or other aspects of protein structure or functions. For example, an agent that acts on a polypeptide and affects its conformation, folding (or other physical characteristics), binding to other moieties (such as ligands), activity (or other functional characteristics), and/or other aspects of protein structure or functions is  
20 considered to have modulated polypeptide function. The ways that an effective agent can act to modulate the function of a polypeptide include, but are not limited to 1) changing the conformation, folding or other physical characteristics; 2) changing the binding strength to its natural ligand or changing the specificity of binding to ligands; and 3) altering the activity of the polypeptide.

25 The terms "modulate susceptibility to development of AIDS" and "modulate resistance to development of AIDS", as used herein, include modulating intra-organism cell-to-cell transmission or infectivity of HIV. The terms further include reducing susceptibility to development of AIDS and/or cell-to-cell transmission or infectivity of HIV. The terms further include increasing resistance to development of AIDS and/or cell-  
30 to-cell transmission or infectivity of HIV. One means of assessing whether an agent is one that modulates susceptibility or resistance to development of AIDS is to determine whether

at least one index of HIV susceptibility is affected, using a cell-based system as described herein, as compared with an appropriate control. Indicia of HIV susceptibility include, but are not limited to, cell-to-cell transmission of the virus, as measured by total number of cells infected with HIV and syncytia formation.

5           The term "target site" means a location in a polypeptide which can beg a single amino acid and/or is a part of, a structural and/or functional motif, e.g., a binding site, a dimerization domain, or a catalytic active site. Target sites may be a useful for direct or indirect interaction with an agent, such as a therapeutic agent.

10           The term "molecular difference" includes any structural and/or functional difference. Methods to detect such differences, as well as examples of such differences, are described herein.

A "functional effect" is a term well known in the art, and means any effect which is exhibited on any level of activity, whether direct or indirect.

15

#### General Procedures Known in the Art

For the purposes of this invention, the source of the human and non-human polynucleotide can be any suitable source, e.g., genomic sequences or cDNA sequences. Preferably, cDNA sequences from human and a non-human primate are compared. Human protein-coding sequences can be obtained from public databases such as the Genome Sequence Data Bank and GenBank. These databases serve as repositories of the molecular sequence data generated by ongoing research efforts. Alternatively, human protein-coding sequences may be obtained from, for example, sequencing of cDNA reverse transcribed from mRNA expressed in human cells, or after PCR amplification, according to methods well known in the art. Alternatively, human genomic sequences may be used for sequence comparison. Human genomic sequences can be obtained from public databases or from a sequencing of commercially available human genomic DNA libraries or from genomic DNA, after PCR.

20

25

30           The non-human primate protein-coding sequences can be obtained by, for example, sequencing cDNA clones that are randomly selected from a non-human primate cDNA library. The non-human primate cDNA library can be constructed from total mRNA

expressed in a primate cell using standard techniques in the art. In some embodiments, the cDNA is prepared from mRNA obtained from a tissue at a determined developmental stage, or a tissue obtained after the primate has been subjected to certain environmental conditions. cDNA libraries used for the sequence comparison of the present invention can  
5 be constructed using conventional cDNA library construction techniques that are explained fully in the literature of the art. Total mRNAs are used as templates to reverse-transcribe cDNAs. Transcribed cDNAs are subcloned into appropriate vectors to establish a cDNA library. The established cDNA library can be maximized for full-length cDNA contents, although less than full-length cDNAs may be used. Furthermore, the sequence frequency  
10 can be normalized according to, for example, Bonaldo *et al.* (1996) *Genome Research* 6:791-806. cDNA clones randomly selected from the constructed cDNA library can be sequenced using standard automated sequencing techniques. Preferably, full-length cDNA clones are used for sequencing. Either the entire or a large portion of cDNA clones from a cDNA library may be sequenced, although it is also possible to practice some embodiments  
15 of the invention by sequencing as little as a single cDNA, or several cDNA clones.

In one preferred embodiment of the present invention, non-human primate cDNA clones to be sequenced can be pre-selected according to their expression specificity. In order to select cDNAs corresponding to active genes that are specifically expressed, the cDNAs can be subject to subtraction hybridization using mRNAs obtained from other  
20 organs, tissues or cells of the same animal. Under certain hybridization conditions with appropriate stringency and concentration, those cDNAs that hybridize with non-tissue specific mRNAs and thus likely represent "housekeeping" genes will be excluded from the cDNA pool. Accordingly, remaining cDNAs to be sequenced are more likely to be associated with tissue-specific functions. For the purpose of subtraction hybridization, non-  
25 tissue-specific mRNAs can be obtained from one organ, or preferably from a combination of different organs and cells. The amount of non-tissue-specific mRNAs are maximized to saturate the tissue-specific cDNAs.

Alternatively, information from online public databases can be used to select or give priority to cDNAs that are more likely to be associated with specific functions. For  
30 example, the non-human primate cDNA candidates for sequencing can be selected by PCR using primers designed from candidate human cDNA sequence. Candidate human cDNA



sequences are, for example, those that are only found in a specific tissue, such as brain, or that correspond to genes likely to be important in the specific function, such as brain function. Such human tissue-specific cDNA sequences can be obtained by searching online human sequence databases such as GenBank, in which information with respect to the expression profile and/or biological activity for cDNA sequences are specified.

Sequences of non-human primate (for example, from an AIDS-resistant non-human primate) homologue(s) to a known human gene may be obtained using methods standard in the art, such as from public databases such as GenBank or PCR methods (using, for example, GeneAmp PCR System 9700 thermocyclers (Applied Biosystems, Inc.)). For example non-human primate cDNA candidates for sequencing can be selected by PCR using primers designed from candidate human cDNA sequences. For PCR, primers may be made from the human sequences using standard methods in the art, including publicly available primer design programs such as PRIMER® (Whitehead Institute). The sequence amplified may then be sequenced using standard methods and equipment in the art, such as automated sequencers (Applied Biosystems, Inc.).

#### GENERAL METHODS OF THE INVENTION

The general method of the invention is as follows. Briefly, nucleotide sequences are obtained from a human source and a non-human source. The human and non-human nucleotide sequences are compared to one another to identify sequences that are homologous. The homologous sequences are analyzed to identify those that have nucleic acid sequence differences between the two species. Then molecular evolution analysis is conducted to evaluate quantitatively and qualitatively the evolutionary significance of the differences. For genes that have been positively selected between two species, e.g., human and chimp, it is useful to determine whether the difference occurs in other non-human primates. Next, the sequence is characterized in terms of molecular/genetic identity and biological function. Finally, the information can be used to identify agents useful in diagnosis and treatment of human medically or commercially relevant conditions.

The general methods of the invention entail comparing human protein-coding nucleotide sequences to protein-coding nucleotide sequences of a non-human, preferably a primate, and most preferably a chimpanzee. Examples of other non-human primates are

bonobo, gorilla, orangutan, gibbon, Old World monkeys, and New World monkeys. A phylogenetic tree for primates within the hominoid group is depicted in FIG. 1.

Bioinformatics is applied to the comparison and sequences are selected that contain a nucleotide change or changes that is/are evolutionarily significant change(s). The invention  
5 enables the identification of genes that have evolved to confer some evolutionary advantage and the identification of the specific evolved changes.

Protein-coding sequences of human and another non-human primate are compared to identify homologous sequences. Any appropriate mechanism for completing this comparison is contemplated by this invention. Alignment may be performed manually or  
10 by software (examples of suitable alignment programs are known in the art). Preferably, protein-coding sequences from a non-human primate are compared to human sequences via database searches, e.g., BLAST searches. The high scoring "hits," i.e., sequences that show a significant similarity after BLAST analysis, will be retrieved and analyzed. Sequences showing a significant similarity can be those having at least about 60%, at least about 75%,  
15 at least about 80%, at least about 85%, or at least about 90% sequence identity. Preferably, sequences showing greater than about 80% identity are further analyzed. The homologous sequences identified via database searching can be aligned in their entirety using sequence alignment methods and programs that are known and available in the art, such as the commonly used simple alignment program CLUSTAL V by Higgins *et al.* (1992) *CABIOS*  
20 8:189-191.

Alternatively, the sequencing and homologous comparison of protein-coding sequences between human and a non-human primate may be performed simultaneously by using the newly developed sequencing chip technology. See, for example, Rava *et al.* US Patent 5,545,531.

25 The aligned protein-coding sequences of human and another non-human primate are analyzed to identify nucleotide sequence differences at particular sites. Again, any suitable method for achieving this analysis is contemplated by this invention. If there are no nucleotide sequence differences, the non-human primate protein coding sequence is not usually further analyzed. The detected sequence changes are generally, and preferably,  
30 initially checked for accuracy. Preferably, the initial checking comprises performing one or more of the following steps, any and all of which are known in the art: (a) finding the

points where there are changes between the non-human primate and human sequences; (b) checking the sequence fluorogram (chromatogram) to determine if the bases that appear unique to non-human primate correspond to strong, clear signals specific for the called base; (c) checking the human hits to see if there is more than one human sequence that  
5 corresponds to a sequence change. Multiple human sequence entries for the same gene that have the same nucleotide at a position where there is a different nucleotide in a non-human primate sequence provides independent support that the human sequence is accurate, and that the change is significant. Such changes are examined using public database information and the genetic code to determine whether these nucleotide sequence changes  
10 result in a change in the amino acid sequence of the encoded protein. As the definition of "nucleotide change" makes clear, the present invention encompasses at least one nucleotide change, either a substitution, a deletion or an insertion, in a human protein-coding polynucleotide sequence as compared to corresponding sequence from a non-human primate. Preferably, the change is a nucleotide substitution. More preferably, more than  
15 one substitution is present in the identified human sequence and is subjected to molecular evolution analysis.

Any of several different molecular evolution analyses or  $K_A/K_S$ -type methods can be employed to evaluate quantitatively and qualitatively the evolutionary significance of the identified nucleotide changes between human gene sequences and that of a non-human  
20 primate. Kreitman and Akashi (1995) *Annu. Rev. Ecol. Syst.* 26:403-422; Li, *Molecular Evolution*, Sinauer Associates, Sunderland, MA, 1997. For example, positive selection on proteins (*i.e.*, molecular-level adaptive evolution) can be detected in protein-coding genes by pairwise comparisons of the ratios of nonsynonymous nucleotide substitutions per nonsynonymous site ( $K_A$ ) to synonymous substitutions per synonymous site ( $K_S$ ) (Li *et al.*,  
25 1985; Li, 1993). Any comparison of  $K_A$  and  $K_S$  may be used, although it is particularly convenient and most effective to compare these two variables as a ratio. Sequences are identified by exhibiting a statistically significant difference between  $K_A$  and  $K_S$  using standard statistical methods.

Preferably, the  $K_A/K_S$  analysis by Li *et al.* is used to carry out the present invention,  
30 although other analysis programs that can detect positively selected genes between species can also be used. Li *et al.* (1985) *Mol. Biol. Evol.* 2:150-174; Li (1993); see also J. Mol.

*Evol.* 36:96-99; Messier and Stewart (1997) *Nature* 385:151-154; Nei (1987) *Molecular Evolutionary Genetics* (New York, Columbia University Press). The  $K_A/K_S$  method, which comprises a comparison of the rate of non-synonymous substitutions per non-synonymous site with the rate of synonymous substitutions per synonymous site between homologous protein-coding region of genes in terms of a ratio, is used to identify sequence substitutions that may be driven by adaptive selections as opposed to neutral selections during evolution. A synonymous ("silent") substitution is one that, owing to the degeneracy of the genetic code, makes no change to the amino acid sequence encoded; a non-synonymous substitution results in an amino acid replacement. The extent of each type of change can be estimated as  $K_A$  and  $K_S$ , respectively, the numbers of synonymous substitutions per synonymous site and non-synonymous substitutions per non-synonymous site. Calculations of  $K_A/K_S$  may be performed manually or by using software. An example of a suitable program is MEGA (Molecular Genetics Institute, Pennsylvania State University).

For the purpose of estimating  $K_A$  and  $K_S$ , either complete or partial human protein-coding sequences are used to calculate total numbers of synonymous and non-synonymous substitutions, as well as non-synonymous and synonymous sites. The length of the polynucleotide sequence analyzed can be any appropriate length. Preferably, the entire coding sequence is compared, in order to determine any and all significant changes. Publicly available computer programs, such as Li93 (Li (1993) *J. Mol. Evol.* 36:96-99) or INA, can be used to calculate the  $K_A$  and  $K_S$  values for all pairwise comparisons. This analysis can be further adapted to examine sequences in a "sliding window" fashion such that small numbers of important changes are not masked by the whole sequence. "Sliding window" refers to examination of consecutive, overlapping subsections of the gene (the subsections can be of any length).

The comparison of non-synonymous and synonymous substitution rates is represented by the  $K_A/K_S$  ratio.  $K_A/K_S$  has been shown to be a reflection of the degree to which adaptive evolution has been at work in the sequence under study. Full length or partial segments of a coding sequence can be used for the  $K_A/K_S$  analysis. The higher the  $K_A/K_S$  ratio, the more likely that a sequence has undergone adaptive evolution and the non-synonymous substitutions are evolutionarily significant. See, for example, Messier and Stewart (1997). Preferably, the  $K_A/K_S$  ratio is at least about 0.75, more preferably at least

about 1.0, more preferably at least about 1.25, more preferably at least about 1.50, or more preferably at least about 2.00. Preferably, statistical analysis is performed on all elevated  $K_A/K_S$  ratios, including, but not limited to, standard methods such as Student's *t*-test and likelihood ratio tests described by Yang (1998) *Mol. Biol. Evol.* 37:441-456.

5  $K_A/K_S$  ratios significantly greater than unity strongly suggest that positive selection has fixed greater numbers of amino acid replacements than can be expected as a result of chance alone, and is in contrast to the commonly observed pattern in which the ratio is less than or equal to one. Nei (1987); Hughes and Nei (1988) *Nature* 335:167-170; Messier and Stewart (1994) *Current Biol.* 4:911-913; Kreitman and Akashi (1995) *Ann. Rev. Ecol. Syst.* 10 26:403-422; Messier and Stewart (1997). Ratios less than one generally signify the role of negative, or purifying selection: there is strong pressure on the primary structure of functional, effective proteins to remain unchanged.

All methods for calculating  $K_A/K_S$  ratios are based on a pairwise comparison of the number of nonsynonymous substitutions per nonsynonymous site to the number of  
15 synonymous substitutions per synonymous site for the protein-coding regions of homologous genes from related species. Each method implements different corrections for estimating "multiple hits" (*i.e.*, more than one nucleotide substitution at the same site). Each method also uses different models for how DNA sequences change over evolutionary time. Thus, preferably, a combination of results from different algorithms is used to  
20 increase the level of sensitivity for detection of positively-selected genes and confidence in the result.

Preferably,  $K_A/K_S$  ratios should be calculated for orthologous gene pairs, as opposed to paralogous gene pairs (*i.e.*, a gene which results from speciation, as opposed to a gene that is the result of gene duplication) Messier and Stewart (1997). This distinction may be  
25 made by performing additional comparisons with other non-human primates, such as gorilla and orangutan, which allows for phylogenetic tree-building. Orthologous genes when used in tree-building will yield the known "species tree", *i.e.*, will produce a tree that recovers the known biological tree. In contrast, paralogous genes will yield trees which will violate the known biological tree.

30 It is understood that the methods described herein could lead to the identification of human polynucleotide sequences that are functionally related to human protein-coding

sequences. Such sequences may include, but are not limited to, non-coding sequences or coding sequences that do not encode human proteins. These related sequences can be, for example, physically adjacent to the human protein-coding sequences in the human genome, such as introns or 5'- and 3'- flanking sequences (including control elements such as promoters and enhancers). These related sequences may be obtained via searching a public human genome database such as GenBank or, alternatively, by screening and sequencing a human genomic library with a protein-coding sequence as probe. Methods and techniques for obtaining non-coding sequences using related coding sequence are well known for one skilled in the art.

The evolutionarily significant nucleotide changes, which are detected by molecular evolution analysis such as the  $K_A/K_S$  analysis, can be further assessed for their unique occurrence in humans (or the non-human primate) or the extent to which these changes are unique in humans (or the non-human primate). For example, the identified changes can be tested for presence/absence in other non-human primate sequences. The sequences with at least one evolutionarily significant change between human and one non-human primate can be used as primers for PCR analysis of other non-human primate protein-coding sequences, and resulting polynucleotides are sequenced to see whether the same change is present in other non-human primates. These comparisons allow further discrimination as to whether the adaptive evolutionary changes are unique to the human lineage as compared to other non-human primates or whether the adaptive change is unique to the non-human primates (i.e., chimpanzee) as compared to humans and other non-human primates. A nucleotide change that is detected in human but not other primates more likely represents a human adaptive evolutionary change. Alternatively, a nucleotide change that is detected in a non-human primate (i.e., chimpanzee) that is not detected in humans or other non-human primates likely represents a chimpanzee adaptive evolutionary change. Other non-human primates used for comparison can be selected based on their phylogenetic relationships with human. Closely related primates can be those within the hominoid sublineage, such as chimpanzee, bonobo, gorilla, and orangutan. Non-human primates can also be those that are outside the hominoid group and thus not so closely related to human, such as the Old World monkeys and New World monkeys. Statistical significance of such comparisons may be determined using established available programs, e.g., *t*-test as used by Messier and

Stewart (1997) *Nature* 385:151-154. Those genes showing statistically high  $K_A/K_S$  ratios are very likely to have undergone adaptive evolution.

Sequences with significant changes can be used as probes in genomes from different human populations to see whether the sequence changes are shared by more than one human population. Gene sequences from different human populations can be obtained from databases made available by, for example, the Human Genome Project, the human genome diversity project or, alternatively, from direct sequencing of PCR-amplified DNA from a number of unrelated, diverse human populations. The presence of the identified changes in different human populations would further indicate the evolutionary significance of the changes. Chimpanzee sequences with significant changes can be obtained and evaluated using similar methods to determine whether the sequence changes are shared among many chimpanzees.

Sequences with significant changes between species can be further characterized in terms of their molecular/genetic identities and biological functions, using methods and techniques known to those of ordinary skill in the art. For example, the sequences can be located genetically and physically within the human genome using publicly available bio-informatics programs. The newly identified significant changes within the nucleotide sequence may suggest a potential role of the gene in human evolution and a potential association with human-unique functional capabilities. The putative gene with the identified sequences may be further characterized by, for example, homologue searching. Shared homology of the putative gene with a known gene may indicate a similar biological role or function. Another exemplary method of characterizing a putative gene sequence is on the basis of known sequence motifs. Certain sequence patterns are known to code for regions of proteins having specific biological characteristics such as signal sequences, DNA binding domains, or transmembrane domains.

The identified human sequences with significant changes can also be further evaluated by looking at where the gene is expressed in terms of tissue- or cell type-specificity. For example, the identified coding sequences can be used as probes to perform *in situ* mRNA hybridization that will reveal the expression patterns of the sequences. Genes that are expressed in certain tissues may be better candidates as being associated with important human functions associated with that tissue, for example brain tissue. The

timing of the gene expression during each stage of human development can also be determined.

As another exemplary method of sequence characterization, the functional roles of the identified nucleotide sequences with significant changes can be assessed by conducting functional assays for different alleles of an identified gene in a model system, such as yeast, nematode, *Drosophila*, and mouse. Model systems may be cell-based or *in vivo*, such as transgenic animals. Preferably, the transgenic mouse system is used. Methods of making cell-based systems and/or transgenic animal systems are known in the art and need not be described in detail herein.

As another exemplary method of sequence characterization, the use of computer programs allows modeling and visualizing the three-dimensional structure of the homologous proteins from human and chimpanzee. Specific, exact knowledge of which amino acids have been replaced in the chimpanzee protein(s) allows detection of structural changes that may be associated with functional differences. Thus, use of modeling techniques is closely associated with identification of functional roles discussed in the previous paragraph. The use of individual or combinations of these techniques constitutes part of the present invention. For example, chimpanzee ICAM-3 contains a glutamine residue (Q101) at the site in which human ICAM-3 contains a proline (P101). The human protein is known to bend sharply at this point. Replacement of the proline by glutamine in the chimpanzee protein is likely to result in a much less sharp bend at this point. This has clear implications for packaging of the ICAM-3 chimpanzee protein into HIV virions.

The sequences identified by the methods described herein have significant uses in diagnosis and treatment of medically or commercially relevant human conditions. Accordingly, the present invention provides methods for identifying agents that are useful in modulating human-unique or human-enhanced functional capabilities and/or correcting defects in these capabilities using these sequences. These methods employ, for example, screening techniques known in the art, such as *in vitro* systems, cell-based expression systems and transgenic animal systems. The approach provided by the present invention not only identifies rapidly evolved genes, but indicates modulations that can be made to the protein that may not be too toxic because they exist in another species.



### *Screening methods*

The present invention also provides screening methods using the polynucleotides and polypeptides identified and characterized using the above-described methods. These  
5 screening methods are useful for identifying agents which may modulate the function(s) of the polynucleotides or polypeptides in a manner that would be useful for a human treatment. Generally, the methods entail contacting at least one agent to be tested with either a cell that has been transfected with a polynucleotide sequence identified by the  
10 methods described above, or a preparation of the polypeptide encoded by such polynucleotide sequence, wherein an agent is identified by its ability to modulate function of either the polynucleotide sequence or the polypeptide.

As used herein, the term "agent" means a biological or chemical compound such as a simple or complex organic or inorganic molecule, a peptide, a protein or an  
15 oligonucleotide. A vast array of compounds can be synthesized, for example oligomers, such as oligopeptides and oligonucleotides, and synthetic organic and inorganic compounds based on various core structures, and these are also included in the term "agent". In addition, various natural sources can provide compounds for screening, such as plant or animal extracts, and the like. Compounds can be tested singly or in combination with one  
20 another.

To "modulate function" of a polynucleotide or a polypeptide means that the function of the polynucleotide or polypeptide is altered when compared to not adding an agent. Modulation may occur on any level that affects function. A polynucleotide or polypeptide function may be direct or indirect, and measured directly or indirectly. A  
25 "function" of a polynucleotide includes, but is not limited to, replication, translation, and expression pattern(s). A polynucleotide function also includes functions associated with a polypeptide encoded within the polynucleotide. For example, an agent which acts on a polynucleotide and affects protein expression, conformation, folding (or other physical characteristics), binding to other moieties (such as ligands), activity (or other functional  
30 characteristics), regulation and/or other aspects of protein structure or function is considered to have modulated polynucleotide function. The ways that an effective agent can

act to modulate the expression of a polynucleotide include, but are not limited to 1) modifying binding of a transcription factor to a transcription factor responsive element in the polynucleotide; 2) modifying the interaction between two transcription factors necessary for expression of the polynucleotide; 3) altering the ability of a transcription factor necessary for expression of the polynucleotide to enter the nucleus; 4) inhibiting the activation of a transcription factor involved in transcription of the polynucleotide; 5) modifying a cell-surface receptor which normally interacts with a ligand and whose binding of the ligand results in expression of the polynucleotide; 6) inhibiting the inactivation of a component of the signal transduction cascade that leads to expression of the polynucleotide; and 7) enhancing the activation of a transcription factor involved in transcription of the polynucleotide.

A "function" of a polypeptide includes, but is not limited to, conformation, folding (or other physical characteristics), binding to other moieties (such as ligands), activity (or other functional characteristics), and/or other aspects of protein structure or functions. For example, an agent that acts on a polypeptide and affects its conformation, folding (or other physical characteristics), binding to other moieties (such as ligands), activity (or other functional characteristics), and/or other aspects of protein structure or functions is considered to have modulated polypeptide function. The ways that an effective agent can act to modulate the function of a polypeptide include, but are not limited to 1) changing the conformation, folding or other physical characteristics; 2) changing the binding strength to its natural ligand or changing the specificity of binding to ligands; and 3) altering the activity of the polypeptide.

Generally, the choice of agents to be screened is governed by several parameters, such as the particular polynucleotide or polypeptide target, its perceived function, its three-dimensional structure (if known or surmised), and other aspects of rational drug design. Techniques of combinatorial chemistry can also be used to generate numerous permutations of candidates. Those of skill in the art can devise and/or obtain suitable agents for testing.

The *in vivo* screening assays described herein may have several advantages over conventional drug screening assays: 1) if an agent must enter a cell to achieve a desired therapeutic effect, an *in vivo* assay can give an indication as to whether the agent can enter a cell; 2) an *in vivo* screening assay can identify agents that, in the state in which they are

added to the assay system are ineffective to elicit at least one characteristic which is associated with modulation polynucleotide or polypeptide function, but that are modified by cellular components once inside a cell in such a way that they become effective agents; 3) most importantly, an *in vivo* assay system allows identification of agents affecting any component of a pathway that ultimately results in characteristics that are associated with polynucleotide or polypeptide function.

In general, screening can be performed by adding an agent to a sample of appropriate cells which have been transfected with a polynucleotide identified using the methods of the present invention, and monitoring the effect, i.e., modulation of a function of the polynucleotide or the polypeptide encoded within the polynucleotide. The experiment preferably includes a control sample which does not receive the candidate agent. The treated and untreated cells are then compared by any suitable phenotypic criteria, including but not limited to microscopic analysis, viability testing, ability to replicate, histological examination, the level of a particular RNA or polypeptide associated with the cells, the level of enzymatic activity expressed by the cells or cell lysates, the interactions of the cells when exposed to infectious agents, such as HIV, and the ability of the cells to interact with other cells or compounds. For example, the transfected cells can be exposed to the agent to be tested and, before, during, or after treatment with the agent, the cells can be infected with a virus, such as HIV, and tested for any indication of susceptibility of the cells to viral infection, including, for example, susceptibility of the cells to cell-to-cell viral infection, replication of the virus, production of a viral protein, and/or syncytia formation following infection with the virus. Differences between treated and untreated cells indicate effects attributable to the candidate agent. Optimally, the agent has a greater effect on experimental cells than on control cells. Appropriate host cells include, but are not limited to, eukaryotic cells, preferably mammalian cells. The choice of cell will at least partially depend on the nature of the assay contemplated.

To test for agents that upregulate the expression of a polynucleotide, a suitable host cell transfected with a polynucleotide of interest, such that the polynucleotide is expressed (as used herein, expression includes transcription and/or translation) is contacted with an agent to be tested. An agent would be tested for its ability to result in increased expression of mRNA and/or polypeptide. Methods of making vectors and transfection are well known

in the art. "Transfection" encompasses any method of introducing the endogenous sequence, including, for example, lipofection, transduction, infection or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector (such as a plasmid) or may be integrated into the host genome.

5 To identify agents that specifically activate transcription, transcription regulatory regions could be linked to a reporter gene and the construct added to an appropriate host cell. As used herein, the term "reporter gene" means a gene that encodes a gene product that can be identified (i.e., a reporter protein). Reporter genes include, but are not limited to, alkaline phosphatase, chloramphenicol acetyltransferase,  $\beta$ -galactosidase, luciferase and  
10 green fluorescence protein (GFP). Identification methods for the products of reporter genes include, but are not limited to, enzymatic assays and fluorimetric assays. Reporter genes and assays to detect their products are well known in the art and are described, for example in Ausubel et al. (1987) and periodic updates. Reporter genes, reporter gene assays, and reagent kits are also readily available from commercial sources. Examples of appropriate  
15 cells include, but are not limited to, fungal, yeast, mammalian, and other eukaryotic cells. A practitioner of ordinary skill will be well acquainted with techniques for transfecting eukaryotic cells, including the preparation of a suitable vector, such as a viral vector; conveying the vector into the cell, such as by electroporation; and selecting cells that have been transformed, such as by using a reporter or drug sensitivity element. The effect of an  
20 agent on transcription from the regulatory region in these constructs would be assessed through the activity of the reporter gene product.

Besides the increase in expression under conditions in which it is normally repressed mentioned above, expression could be decreased when it would normally be expressed. An agent could accomplish this through a decrease in transcription rate and the  
25 reporter gene system described above would be a means to assay for this. The host cells to assess such agents would be need to be permissive for expression.

Cells transcribing mRNA (from the polynucleotide of interest) could be used to identify agents that specifically modulate the half-life of mRNA and/or the translation of mRNA. Such cells would also be used to assess the effect of an agent on the processing  
30 and/or post-translational modification of the polypeptide. An agent could modulate the amount of polypeptide in a cell by modifying the turn-over (i.e., increase or decrease the

half-life) of the polypeptide. The specificity of the agent with regard to the mRNA and polypeptide would be determined by examining the products in the absence of the agent and by examining the products of unrelated mRNAs and polypeptides. Methods to examine mRNA half-life, protein processing, and protein turn-over are well known to those skilled in the art.

*In vivo* screening methods could also be useful in the identification of agents that modulate polypeptide function through the interaction with the polypeptide directly. Such agents could block normal polypeptide-ligand interactions, if any, or could enhance or stabilize such interactions. Such agents could also alter a conformation of the polypeptide. The effect of the agent could be determined using immunoprecipitation reactions: Appropriate antibodies would be used to precipitate the polypeptide and any protein tightly associated with it. By comparing the polypeptides immunoprecipitated from treated cells and from untreated cells, an agent could be identified that would augment or inhibit polypeptide-ligand interactions, if any. Polypeptide-ligand interactions could also be assessed using cross-linking reagents that convert a close, but noncovalent interaction between polypeptides into a covalent interaction. Techniques to examine protein-protein interactions are well known to those skilled in the art. Techniques to assess protein conformation are also well known to those skilled in the art.

It is also understood that screening methods can involve *in vitro* methods, such as cell-free transcription or translation systems. In those systems, transcription or translation is allowed to occur, and an agent is tested for its ability to modulate function. For an assay that determines whether an agent modulates the translation of mRNA or a polynucleotide, an *in vitro* transcription/translation system may be used. These systems are available commercially and provide an *in vitro* means to produce mRNA corresponding to a polynucleotide sequence of interest. After mRNA is made, it can be translated *in vitro* and the translation products compared. Comparison of translation products between an *in vitro* expression system that does not contain any agent (negative control) with an *in vitro* expression system that does contain an agent indicates whether the agent is affecting translation. Comparison of translation products between control and test polynucleotides indicates whether the agent, if acting on this level, is selectively affecting translation (as opposed to affecting translation in a general, non-selective or non-specific fashion). The

modulation of polypeptide function can be accomplished in many ways including, but not limited to, the *in vivo* and *in vitro* assays listed above as well as in *in vitro* assays using protein preparations. Polypeptides can be extracted and/or purified from natural or recombinant sources to create protein preparations. An agent can be added to a sample of a protein preparation and the effect monitored; that is whether and how the agent acts on a polypeptide and affects its conformation, folding (or other physical characteristics), binding to other moieties (such as ligands), activity (or other functional characteristics), and/or other aspects of protein structure or functions is considered to have modulated polypeptide function.

In an example for an assay for an agent that binds to a polypeptide encoded by a polynucleotide identified by the methods described herein, a polypeptide is first recombinantly expressed in a prokaryotic or eukaryotic expression system as a native or as a fusion protein in which a polypeptide (encoded by a polynucleotide identified as described above) is conjugated with a well-characterized epitope or protein. Recombinant polypeptide is then purified by, for instance, immunoprecipitation using appropriate antibodies or anti-epitope antibodies or by binding to immobilized ligand of the conjugate. An affinity column made of polypeptide or fusion protein is then used to screen a mixture of compounds which have been appropriately labeled. Suitable labels include, but are not limited to fluorochromes, radioisotopes, enzymes and chemiluminescent compounds. The unbound and bound compounds can be separated by washes using various conditions (e.g. high salt, detergent ) that are routinely employed by those skilled in the art. Non-specific binding to the affinity column can be minimized by pre-clearing the compound mixture using an affinity column containing merely the conjugate or the epitope. Similar methods can be used for screening for an agent(s) that competes for binding to polypeptides. In addition to affinity chromatography, there are other techniques such as measuring the change of melting temperature or the fluorescence anisotropy of a protein which will change upon binding another molecule. For example, a BIAcore assay using a sensor chip (supplied by Pharmacia Biosensor, Stitt *et al.* (1995) *Cell* 80: 661-670) that is covalently coupled to polypeptide may be performed to determine the binding activity of different agents.

It is also understood that the *in vitro* screening methods of this invention include structural, or rational, drug design, in which the amino acid sequence, three-dimensional atomic structure or other property (or properties) of a polypeptide provides a basis for designing an agent which is expected to bind to a polypeptide. Generally, the design and/or  
5 choice of agents in this context is governed by several parameters, such as side-by-side comparison of the structures of a human and homologous non-human primate polypeptides, the perceived function of the polypeptide target, its three-dimensional structure (if known or surmised), and other aspects of rational drug design. Techniques of combinatorial chemistry can also be used to generate numerous permutations of candidate agents.

10 Also contemplated in screening methods of the invention are transgenic animal systems, which are known in the art.

The screening methods described above represent primary screens, designed to detect any agent that may exhibit activity that modulates the function of a polynucleotide or polypeptide. The skilled artisan will recognize that secondary tests will likely be necessary  
15 in order to evaluate an agent further. For example, a secondary screen may comprise testing the agent(s) in an infectivity assay using mice and other animal models (such as rat), which are known in the art. In addition, a cytotoxicity assay would be performed as a further corroboration that an agent which tested positive in a primary screen would be suitable for use in living organisms. Any assay for cytotoxicity would be suitable for this  
20 purpose, including, for example the MTT assay (Promega).

The invention also includes agents identified by the screening methods described herein.

## 25 METHODS USEFUL FOR IDENTIFYING POSITIVELY SELECTED NON-HUMAN TRAITS

In one aspect of the invention, a non-human primate polynucleotide or polypeptide has undergone natural selection that resulted in a positive evolutionarily significant change (i.e., the non-human primate polynucleotide or polypeptide has a positive attribute not present in humans). In this aspect of the invention, the positively selected polynucleotide  
30 or polypeptide may be associated with susceptibility or resistance to certain diseases or with other commercially relevant traits. Examples of this embodiment include, but are not

limited to, polynucleotides and polypeptides that have been positively selected in non-human primates, preferably chimpanzees, that may be associated with susceptibility or resistance to infectious diseases, cancer, or acne or may be associated with aesthetic conditions of interest to humans, such as hair growth or muscle mass. An example of this embodiment includes polynucleotides and polypeptides associated with the susceptibility or resistance to HIV progression to AIDS. The present invention can thus be useful in gaining insight into the molecular mechanisms that underlie resistance to HIV infection progressing to development of AIDS, providing information that can also be useful in discovering and/or designing agents such as drugs that prevent and/or delay development of AIDS. Commercially relevant examples include, but are not limited to, polynucleotides and polypeptides that are positively selected in non-human primates that may be associated with aesthetic traits, such as hair growth, acne, or muscle mass.

Accordingly, in one aspect, the invention provides methods for identifying a polynucleotide sequence encoding a polypeptide, wherein said polypeptide may be associated with a medically relevant positive evolutionarily significant change. The positive evolutionarily significant change can be found in humans or in non-human primates, but the positively selected non-human primate evolutionarily significant change will be described first herein. The method comprises the steps of: (a) comparing human protein-coding nucleotide sequences to protein-coding nucleotide sequences of a non-human primate; and (b) selecting a human polynucleotide sequence that contains at least one nucleotide change as compared to corresponding sequence of the non-human primate, wherein said change is evolutionarily significant. The sequences identified by this method may be further characterized and/or analyzed for their possible association with biologically or medically relevant functions unique or enhanced in humans.

Also provided in the present invention is a method for identifying a positive evolutionarily significant change within human protein-coding nucleotide sequences, comprising the steps of: (a) comparing human protein-coding nucleotide sequences to corresponding sequences of a non-human primate; and (b) selecting a human polynucleotide sequence that contains at least one nucleotide change as compared to the corresponding sequence of the non-human primate, wherein said change is evolutionarily significant.



METHODS USEFUL FOR IDENTIFYING POSITIVELY SELECTED HUMAN TRAITS

5 This invention specifically provides methods for identifying human polynucleotide and polypeptide sequences that may be associated with unique or enhanced functional capabilities of the human, for example, brain function or longer life span. More particularly, these methods identify those genetic sequences that may be associated with capabilities that are unique or enhanced in humans, including, but not limited to, brain functions such as high capacity information processing, storage and retrieval capabilities, 10 creativity, and language abilities. Moreover, these methods identify those sequences that may be associated to other brain functional features with respect to which the human brain performs at enhanced levels as compared to other non-human primates; these differences may include brain-mediated emotional response, locomotion, pain/pleasure sensation, olfaction, temperament and longer life span

15 In this method, the general methods of the invention are applied as described above. Generally, the methods described herein entail (a) comparing human protein-coding polynucleotide sequences to that of a non-human primate; and (b) selecting those human protein-coding polynucleotide sequences having evolutionarily significant changes that may be associated with unique or enhanced functional capabilities of the human as compared to that of the non-human primate. 20

In this embodiment, the human sequence includes the evolutionarily significant change (i.e., the human sequence differs from more than one non-human primate species sequence in a manner that suggests that such a change is in response to a selective pressure). The identity and function of the protein encoded by the gene that contains the evolutionarily significant change is characterized and a determination is made whether or 25 not the protein can be involved in a unique or enhanced human function. If the protein is involved in a unique or enhanced human function, the information is used in a manner to identify agents that can supplement or otherwise modulate the unique or enhanced human function.

30 As a non-limiting example of the invention, identifying the genetic (i.e., nucleotide sequence) differences underlying the functional uniqueness of human brain may

provide a basis for designing agents that can modulate human brain functions and/or help correct functional defects. These sequences could also be used in developing diagnostic reagents and/or biomedical research tools. The invention also provides methods for a large-scale comparison of human brain protein-coding sequences with that from a non-human primate.

The identified human sequence changes can be used in establishing a database of candidate human genes that may be involved in human brain function. Candidates are ranked as to the likelihood that the gene is responsible for the unique or enhanced functional capabilities found in the human brain compared to chimpanzee or other non-human primates. Moreover, the database not only provides an ordered collection of candidate genes, it also provides the precise molecular sequence differences that exist between human and chimpanzee (and other non-human primates), and thus defines the changes that underlie the functional differences. This information can be useful in the identification of potential sites on the protein that may serve as useful targets for pharmaceutical agents.

Accordingly, the present invention also provides methods for correlating an evolutionarily significant nucleotide change to a brain functional capability that is unique or enhanced in humans, comprising (a) identifying a human nucleotide sequence according to the methods described above; and (b) analyzing the functional effect of the presence or absence of the identified sequence in a model system.

Further studies can be carried out to confirm putative function. For example, the putative function can be assayed in appropriate in vitro assays using transiently or stably transfected mammalian cells in culture, or using mammalian cells transfected with an antisense clone to inhibit expression of the identified polynucleotide to assess the effect of the absence of expression of its encoded polypeptide. Studies such as one-hybrid and two-hybrid studies can be conducted to determine, for example, what other macromolecules the polypeptide interacts with. Transgenic nematodes or *Drosophila* can be used for various functional assays, including behavioral studies. The appropriate studies depend on the nature of the identified polynucleotide and the polypeptide encoded within the polynucleotide, and would be obvious to those skilled in the art.

Description of the AIDS Embodiment (an example of a positively selected non-human trait)

The AIDS (Acquired Immune Deficiency Syndrome) epidemic has been estimated to threaten 30 million people world-wide (UNAIDS/WHO, 1998, "Report on the global HIV/AIDS epidemic"). Well over a million people are infected in developed countries, and in parts of sub-Saharan Africa, 1 in 4 adults now carries the virus (UNAIDS/WHO, 1998). Although efforts to develop vaccines are underway, near term prospects for successful vaccines are grim. Balter and Cohen (1998) *Science* 281:159-160; Baltimore and Heilman (1998) *Scientific Am.* 279:98-103. Further complicating the development of therapeutics is the rapid mutation rate of HIV (the human immunodeficiency virus which is responsible for AIDS), which generates rapid changes in viral proteins. These changes ultimately allow the virus to escape current therapies, which target viral proteins. Dobkin (1998) *Inf. Med.* 15(3):159. Even drug cocktails which initially showed great promise are subject to the emergence of drug-resistant mutants. Balter and Cohen (1998); Dobkin (1998). Thus, there is still a serious need for development of therapies which delay or prevent progression of AIDS in HIV-infected individuals. Chun *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94:13193-13197; Dobkin (1998).

Human's closest relatives, chimpanzees (*Pan troglodytes*), have unexpectedly proven to be poor models for the study of the disease processes following infection with HIV-1. Novembre *et al.* (1997); *J. Virol.* 71(5):4086-4091. Once infected with HIV-1, chimpanzees display resistance to progression of the disease. To date, only one chimpanzee individual is known to have developed full-blown AIDS, although more than 100 captive chimpanzees have been infected. Novembre *et al.* (1997); Villinger *et al.* (1997) *J. Med. Primatol.* 26(1-2):11-18. Clearly, an understanding of the mechanism(s) that confer resistance to progression of the disease in chimpanzees may prove invaluable for efforts to develop therapeutic agents for HIV-infected humans.

It is generally believed that wild chimpanzee populations harbored the HIV-1 virus (perhaps for millennia) prior to its recent cross-species transmission to humans. Dube *et al.*, (1994); *Virology* 202:379-389; Zhu and Ho (1995) *Nature* 374:503-504; Zhu *et al.* (1998); Quinn (1994) *Proc. Natl. Acad. Sci. USA* 91:2407-2414. During this extended period, viral/host co-evolution has apparently resulted in accommodation, explaining

chimpanzee resistance to AIDS progression. Burnet and White (1972); *Natural History of Infectious Disease* (Cambridge, Cambridge Univ. Press); Ewald (1991) *Hum. Nat.* 2(i):1-30. All references cited herein are hereby incorporated by reference in their entirety.

One aspect of this invention arises from the observations that (a) because  
5 chimpanzees (*Pan troglodytes*) have displayed resistance to development of AIDS although susceptible to HIV infection (Alter *et al.* (1984) *Science* 226:549-552; Fultz *et al.* (1986) *J. Virol.* 58:116-124; Novembre *et al.* (1997) *J. Virol.* 71(5):4086-4091), while humans are susceptible to developing this devastating disease, certain genes in chimpanzees may contribute to this resistance; and (b) it is possible to evaluate whether changes in human  
10 genes when compared to homologous genes from other species (such as chimpanzee) are evolutionarily significant (*i.e.*, indicating positive selective pressure). Thus, protein coding polynucleotides may contain sequence changes that are found in chimpanzees (as well as other AIDS-resistant primates) but not in humans, likely as a result of positive adaptive selection during evolution. Furthermore, such evolutionarily significant changes in  
15 polynucleotide and polypeptide sequences may be attributed to an AIDS-resistant non-human primate's (such as chimpanzee) ability to resist development of AIDS. The methods of this invention employ selective comparative analysis to identify candidate genes which may be associated with susceptibility or resistance to AIDS, which may provide new host targets for therapeutic intervention as well as specific information on the changes that evolved to confer resistance. Development of therapeutic approaches that involve host  
20 proteins (as opposed to viral proteins and/or mechanisms) may delay or even avoid the emergence of resistant viral mutants. The invention also provides screening methods using the sequences and structural differences identified.

This invention provides methods for identifying human polynucleotide and  
25 polypeptide sequences that may be associated with susceptibility to post-infection development of AIDS. Conversely, the invention also provides methods for identifying polynucleotide and polypeptide sequences from an AIDS-resistant non-human primate (such as chimpanzee) that may be associated with resistance to development of AIDS. Identifying the genetic (*i.e.*, nucleotide sequence) and the resulting protein structural and  
30 biochemical differences underlying susceptibility or resistance to development of AIDS will likely provide a basis for discovering and/or designing agents that can provide

prevention and/or therapy for HIV infection progressing to AIDS. These differences could also be used in developing diagnostic reagents and/or biomedical research tools. For example, identification of proteins which confer resistance may allow development of diagnostic reagents or biomedical research tools based upon the disruption of the disease pathway of which the resistant protein plays a part.

Generally, the methods described herein entail (a) comparing human protein-coding polynucleotide sequences to that of an AIDS resistant non-human primate (such as chimpanzee), wherein the human protein coding polynucleotide sequence is associated with development of AIDS; and (b) selecting those human protein-coding polynucleotide sequences having evolutionarily significant changes that may be associated with susceptibility to development of AIDS. In another embodiment, the methods entail (a) comparing human protein-coding polynucleotide sequences to that of an AIDS-resistant non-human primate (such as chimpanzee), wherein the human protein coding polynucleotide sequence is associated with development of AIDS; and (b) selecting those non-human primate protein-coding polynucleotide sequences having evolutionarily significant changes that may be associated with resistance to development of AIDS.

As is evident, the methods described herein can be applied to other infectious diseases. For example, the methods could be used in a situation in which a non-human primate is known or believed to have harbored the infectious disease for a significant period (i.e., a sufficient time to have allowed positive selection) and is resistant to development of the disease. Thus, in other embodiments, the invention provides methods for identifying a polynucleotide sequence encoding a polypeptide, wherein said polypeptide may be associated with resistance to development of an infectious disease, comprising the steps of: (a) comparing infectious disease-resistant non-human primate protein coding sequences to human protein coding sequences, wherein the human protein coding sequence is associated with development of the infectious disease; and (b) selecting an infectious disease-resistant non-human primate sequence that contains at least one nucleotide change as compared to the corresponding human sequence, wherein the nucleotide change is evolutionarily significant. In another embodiment, the invention provides methods for identifying a human polynucleotide sequence encoding a polypeptide, wherein said polypeptide may be associated with susceptibility to development of an infectious disease, comprising the steps

of: (a) comparing human protein coding sequences to protein-coding polynucleotide sequences of an infectious disease-resistant non-human primate, wherein the human protein coding sequence is associated with development of the infectious disease; and (b) selecting a human polynucleotide sequence that contains at least one nucleotide change as compared to the corresponding sequence of an infectious disease-resistant non-human primate, wherein the nucleotide change is evolutionarily significant.

In the present invention, human sequences to be compared with a homologue from an AIDS-resistant non-human primate are selected based their known or implicated association with HIV propagation (*i.e.*, replication), dissemination and/or subsequent progression to AIDS. Such knowledge is obtained, for example, from published literature and/or public databases (including sequence databases such as GenBank). Because the pathway involved in development of AIDS (including viral replication) involves many genes, a number of suitable candidates may be tested using the methods of this invention. Table 1 contains a exemplary list of genes to be examined. The sequences are generally known in the art.

**Table 1: Sample List of Human Genes to be/have been Examined**

<u>Gene</u>	<u>Function</u>
eIF-5A	Initiation factor
hPC6A	Protease
hPC6B	Protease
P56 <sup>lck</sup>	Signal transduction
FK506-binding protein	Immunophilin
calnexin	?
Bax	PCD promoter
bcl-2	apoptosis inhibitor
lck	tyrosine kinase
MAPK (mitogen activated protein kinase)	protein kinase
CD43	sialoglycoprotein

	CCR2B	chemokine receptor	
	CCR3	chemokine receptor	
5	Bonzo	chemokine receptor	
	BOB	chemokine receptor	
	GPR1	chemokine receptor	
10	stromal-derived factor-1 (SDF-1)	chemokine	
	tumor-necrosis factor- $\alpha$ (TNF- $\alpha$ )		PCD promoter
	TNF-receptor II (TNFRII)		receptor
15	interferon $\gamma$ (IFN- $\gamma$ )	cytokine	
	interleukin 1 $\alpha$ (IL-1 $\alpha$ )	cytokine	
	interleukin 1 $\beta$ (IL-1 $\beta$ )	cytokine	
20	interleukin 2 (IL-2)	cytokine	
	interleukin 4 (IL-4)	cytokine	
25	interleukin 6 (IL-6)	cytokine	
	interleukin 10 (IL-10)	cytokine	
	interleukin 13 (IL-13)	cytokine	
30	B7	signaling protein	
	macrophage colony-stimulating factor (M-CSF)		cytokine
	granulocyte-macrophage colony-stimulating factor		cytokine
35	phosphatidylinositol 3-kinase (PI 3-kinase)		kinase
	phosphatidylinositol 4-kinase (PI 4-kinase)		kinase
	HLA class I $\alpha$ chain		
	histocompatibility antigen		
	$\beta_2$ microglobulin		
40	lymphocyte antigen		
	CD55	decay-accelerating factor	
	CD59	complement protein	
45	CD63	glycoprotein antigen	
	CD71		

	?		
	interferon $\alpha$ (IFN- $\alpha$ )		
	cytokine		
	CD44		
5	cell adhesion		
	CD8		
	glycoprotein		
10	Genes already examined (12)		
	ICAM-1		
	Immune system		
	ICAM-2		
15	Immune system		
	ICAM-3		
	Immune system		
	leukocyte associated function 1 molecule $\alpha$ (LFA-1)	Immune system	
	leukocyte associated function 1 molecule $\beta$ (LFA-1)	Immune system	
20	Mac-1 $\alpha$		
	Immune system		
	Mac-1 $\beta$ (equivalent to LFA-1 $\beta$ )		
	system		Immune
	CXCR4		
25	chemokine receptor		
	CCR5		
	chemokine receptor		
	MIP-1 $\alpha$		
	chemokine		
30	MIP-1 $\beta$		
	chemokine		
	RANTES		
	chemokine		

35 Aligned protein-coding sequences of human and an AIDS resistant non-human primate such as chimpanzee are analyzed to identify nucleotide sequence differences at particular sites. The detected sequence changes are generally, and preferably, initially checked for accuracy as described above. The evolutionarily significant nucleotide changes, which are detected by molecular evolution analysis such as the  $K_A/K_S$  analysis, can

40 be further assessed to determine whether the non-human primate gene or the human gene has been subjected to positive selection. For example, the identified changes can be tested for presence/absence in other AIDS- resistant non-human primate sequences. The



sequences with at least one evolutionarily significant change between human and one AIDS-resistant non-human primate can be used as primers for PCR analysis of other non-human primate protein-coding sequences, and resulting polynucleotides are sequenced to see whether the same change is present in other non-human primates. These comparisons  
5 allow further discrimination as to whether the adaptive evolutionary changes are unique to the AIDS-resistant non-human primate (such as chimpanzee) as compared to other non-human primates. For example, a nucleotide change that is detected in chimpanzee but not other primates more likely represents positive selection on the chimpanzee gene. Other non-human primates used for comparison can be selected based on their phylogenetic  
10 relationships with human. Closely related primates can be those within the hominoid sublineage, such as chimpanzee, bonobo, gorilla, and orangutan. Non-human primates can also be those that are outside the hominoid group and thus not so closely related to human, such as the Old World monkeys and New World monkeys. Statistical significance of such comparisons may be determined using established available programs, *e.g.*, *t*-test as used by  
15 Messier and Stewart (1997) *Nature* 385:151-154.

Furthermore, sequences with significant changes can be used as probes in genomes from different humans to see whether the sequence changes are shared by more than one individual. For example, certain individuals are slower to progress to AIDS ("slow progressers") and comparison (a) between a chimpanzee sequence and the homologous  
20 sequence from the slow-progresser human individual and/or (b) between an AIDS-susceptible individual and a slow-progresser individual would be of interest. Gene sequences from different human populations can be obtained from databases made available by, for example, the human genome diversity project or, alternatively, from direct sequencing of PCR-amplified DNA from a number of unrelated, diverse human  
25 populations. The presence of the identified changes in human slow progressers would further indicate the evolutionary significance of the changes.

The following examples are provided to further assist those of ordinary skill in the art. Such examples are intended to be illustrative and therefore should not be regarded as limiting the invention. A number of exemplary modifications and variations are described  
30 in this application and others will become apparent to those of skill in this art. Such

variations are considered to fall within the scope of the invention as described and claimed herein.

## EXAMPLES

### 5 EXAMPLE 1: cDNA Library Construction

A chimpanzee cDNA library is constructed using chimpanzee tissue.

Total RNA is extracted from the tissue (RNeasy kit, Qiagen; RNase-free Rapid  
Total RNA kit, 5 Prime--3 Prime, Inc.) and the integrity and purity of the RNA are  
10 determined according to conventional molecular cloning methods. Poly A+ RNA is  
isolated (Mini-Oligo(dT) Cellulose Spin Columns, 5 Prime--3 Prime, Inc.) and used as  
template for the reverse-transcription of cDNA with oligo (dT) as a primer. The  
synthesized cDNA is treated and modified for cloning using commercially available kits.  
Recombinants are then packaged and propagated in a host cell line. Portions of the  
15 packaging mixes are amplified and the remainder retained prior to amplification. The  
library can be normalized and the numbers of independent recombinants in the library is  
determined.

### EXAMPLE 2: Sequence Comparison

20 Suitable primers based on a candidate human gene are prepared and used for PCR  
amplification of chimpanzee cDNA either from a cDNA library or from cDNA prepared  
from mRNA. Selected chimpanzee cDNA clones from the cDNA library are sequenced  
using an automated sequencer, such as an ABI 377. Commonly used primers on the  
cloning vector such as the M13 Universal and Reverse primers are used to carry out the  
25 sequencing. For inserts that are not completely sequenced by end sequencing, dye-labeled  
terminators are used to fill in remaining gaps.

The detected sequence differences are initially checked for accuracy, for example by  
finding the points where there are differences between the chimpanzee and human  
sequences; checking the sequence fluorogram (chromatogram) to determine if the bases that  
30 appear unique to human correspond to strong, clear signals specific for the called base;

checking the human hits to see if there is more than one human sequence that corresponds to a sequence change; and other methods known in the art, as needed. Multiple human sequence entries for the same gene that have the same nucleotide at a position where there is a different chimpanzee nucleotide provides independent support that the human sequence is accurate, and that the chimpanzee/human difference is real. Such changes are examined using public database information and the genetic code to determine whether these DNA sequence changes result in a change in the amino acid sequence of the encoded protein. The sequences can also be examined by direct sequencing of the encoded protein.

### **EXAMPLE 3: Molecular Evolution Analysis**

The chimpanzee and human sequences under comparison are subjected to  $K_A/K_S$  analysis. In this analysis, publicly available computer programs, such as Li 93 and INA, are used to determine the number of non-synonymous changes per site ( $K_A$ ) divided by the number of synonymous changes per site ( $K_S$ ) for each sequence under study as described above. Full-length coding regions or partial segments of a coding region can be used. The higher the  $K_A/K_S$  ratio, the more likely that a sequence has undergone adaptive evolution. Statistical significance of  $K_A/K_S$  values is determined using established statistic methods and available programs such as the *t*-test.

To further lend support to the significance of a high  $K_A/K_S$  ratio, the sequence under study can be compared in multiple chimpanzee individuals and in other non-human primates, *e.g.*, gorilla, orangutan, bonobo. These comparisons allow further discrimination as to whether the adaptive evolutionary changes are unique to the human lineage compared to other non-human primates. The sequences can also be examined by direct sequencing of the gene of interest from representatives of several diverse human populations to assess to what degree the sequence is conserved in the human species.

### **EXAMPLE 4: Identification of positively selected ICAM-1, ICAM-2 and ICAM-3**

Using the methods of the invention described herein, the intercellular adhesion molecules ICAM-1, ICAM-2 and ICAM-3 have been shown to have been strongly positively selected. The ICAM molecules are involved in several immune response interactions and are known to play a role in progression to AIDS in HIV infected humans.

The ICAM proteins, members of the Ig superfamily, are ligands for the integrin leukocyte associated function 1 molecule (LFA-1). Makgoba *et al.* (1988) *Nature* 331:86-88. LFA-1 is expressed on the surface of most leukocytes, while ICAMs are expressed on the surface of both leukocytes and other cell types. Larson *et al.* (1989) *J. Cell Biol.* 108:703-712.

5 ICAM and LFA-1 proteins are involved in several immune response interactions, including T-cell function, and targeting of leukocytes to areas of inflammation. Larson *et al.* (1989).

Total RNA was prepared using either the RNeasy kit (Qiagen), or the RNase-free Rapid Total RNA kit (5 Prime - 3 Prime, Inc.) from primate tissues (chimpanzee brain and blood, gorilla blood and spleen, orangutan blood) or from cells harvested from the  
10 following B lymphocyte cell lines: CARL (chimpanzee), ROK (gorilla), and PUTI (orangutan). mRNA was isolated from total RNA using the Mini-Oligo(dT) Cellulose Spin Columns (5 Prime - 3 Prime, Inc.). cDNA was synthesized from mRNA with oligo dT and/or random priming using the cDNA Synthesis Kit (Stratagene). The protein-coding region of the primate ICAM-1 gene was amplified from cDNA using primers  
15 (concentration=100 nmole/ $\mu$ l) designed by hand from the published human sequence. PCR conditions for ICAM-1 amplification were 94°C initial pre-melt (4 min), followed by 35 cycles of 94°C (15 sec), 58°C (1 min 15 sec), 72°C (1 min 15 sec), and a final 72°C extension for 10 minutes. PCR was accomplished using Ready-to-Go PCR beads (Amersham Pharmacia Biotech) in a 50 microliter total reaction volume. Appropriately-  
20 sized products were purified from agarose gels using the QiaQuick Gel Extraction kit (Qiagen). Both strands of the amplification products were sequenced directly using the Big Dye Cycle Sequencing Kit and analyzed on a 373A DNA sequencer (ABI BioSystems).

Comparison of the protein-coding portions of the human, gorilla (*Gorilla gorilla*), and orangutan (*Pongo pygmaeus*) ICAM-1 genes to that of the chimpanzee yielded  
25 statistically significant  $K_A/K_S$  ratios (Table 2). The protein-coding portions of the human and chimpanzee ICAM-1 genes were previously published and the protein-coding portions of gorilla (*Gorilla gorilla*), and orangutan (*Pongo pygmaeus*) ICAM-1 genes are shown in Figures 3 and 4, respectively.

For this experiment, pairwise  $K_A/K_S$  ratios were calculated for the mature protein  
30 using the algorithm of Li (1985; 1993). Statistically significant comparisons (determined by *t*-tests) are shown in bold. Although the comparison to gorilla and human was sufficient

to demonstrate that chimpanzee ICAM-1 has been positively-selected, the orangutan ICAM-1 was compared as well, since the postulated historical range of gorillas in Africa suggests that gorillas could have been exposed to the HIV-1 virus. Nowak and Paradiso (1983) *Walker's Mammals of the World* (Baltimore, MD, The Johns Hopkins University Press). The orangutan, however, has always been confined to Southeast Asia and is thus unlikely to have been exposed to HIV over an evolutionary time frame. (Nowak and Paradiso, 1983) (Gorillas are most closely-related to humans and chimpanzees, while orangutans are more distantly-related.)

**Table 2.  $K_A/K_S$  Ratios: ICAM-1 Whole Protein Comparisons**

<b>Species Compared</b>	<b><math>K_A/K_S</math> Ratio</b>
Chimpanzee to Human	<b>2.1</b> ( $P < 0.01$ )
Chimpanzee to Gorilla	<b>1.9</b> ( $P < 0.05$ )
Chimpanzee to Orangutan	<b>1.4</b> ( $P < 0.05$ )
Human to Gorilla	1.0
Human to Orangutan	0.87
Gorilla to Orangutan	0.95

10

Even among those proteins for which positive selection has been demonstrated, few show  $K_A/K_S$  ratios as high as these ICAM-1 comparisons. Lee and Vacquier (1992) *Biol. Bull.* 182:97-104; Swanson and Vacquier (1995) *Proc. Natl. Acad. Sci. USA* 92:4957-4961; Messier and Stewart (1997); Sharp (1997) *Nature* 385:111-112. The results are consistent with strong selective pressure resulting in adaptive changes in the chimpanzee ICAM-1 molecule.

15

The domains (D1 and D2) of the ICAM-1 molecule which bind to LFA-1 have been documented. Staunton *et al.* (1990). *Cell* 61:243-254. Pairwise  $K_A/K_S$  comparisons between primate ICAM-1 genes.  $K_A/K_S$  ratios were calculated for domains D1 and D2 only, using the algorithm of Li (1985; 1993) (Table 3). Statistically significant comparisons (determined by *t*-tests) are shown in bold. The very high, statistically significant  $K_A/K_S$  ratios for domains D1 and D2 suggest that these regions of the protein were very strongly positively-selected. These regions of chimpanzee ICAM-1 display even more striking  $K_A/K_S$  ratios (Table 3) than are seen for the whole protein comparisons, thus

20

suggesting that the ICAM-1/LFA-1 interaction has been subjected to unusually strong selective pressures.

**Table 3.  $K_A/K_S$  Ratios: Domains D1+D2 of ICAM-1**

Species Compared	$K_A/K_S$ Ratio
Chimpanzee to Human	3.1 (P < 0.01)
Chimpanzee to Gorilla	2.5 (P < 0.05)
Chimpanzee to Orangutan	1.5 (P < 0.05)
Human to Gorilla	1.0
Human to Orangutan	0.90
Gorilla to Orangutan	1.0

Essentially the same procedures were used to identify as positively selected chimpanzee ICAM-2 and ICAM-3 (see Table 4). The ligand binding domain of ICAM-1 has been localized as exhibiting especially striking positive selection in contrast to ICAMs - 2 and -3, for which positive selection resulted in amino acid replacements throughout the protein. Thus, this comparative genomic analysis reveals that positive selection on ICAMs in chimpanzees has altered the proteins' primary structure, for example, in important binding domains. These alterations may have conferred resistance to AIDS progression in chimpanzees.

**Table 4.  $K_A/K_S$  Ratios: ICAM-2 and 3 Whole Protein Comparisons**

Species Compared	$K_A/K_S$ Ratio
Chimpanzee to Human ICAM-2	2.1 (P < 0.01)
Chimpanzee to Human ICAM-3	3.7 (P < 0.01)

Binding of ICAM-1, -2, and -3 has been demonstrated to play an essential role in the formation of syncytia (*i.e.*, giant, multi-nucleated cells) in HIV-infected cells *in vitro*. Pantaleo *et al.* (1991) *J. Ex. Med.* 173:511-514. Syncytia formation is followed by the depletion of CD<sup>+</sup> cells *in vitro*. Pantaleo *et al.* (1991); Levy (1993) *Microbiol. Rev.* 57:183-189; Butini *et al.* (1994) *Eur. J. Immunol.* 24:2191-2195; Finkel and Banda (1994) *Curr. Opin. Immunol.* 6:605-615. Although syncytia formation is difficult to detect *in vivo*, clusters of infected cells are seen in lymph nodes of infected individuals. Pantaleo *et al.*, (1993) *N. Eng. J. Med.* 328:327-335; Finkel and Banda (1994); Embretson *et al.* (1993)

*Nature* 362:359-362; Pantaleo *et al.* (1993) *Nature* 362:355-358. Syncytia may simply be scavenged from the body too quickly to be detected. Fouchier *et al.* (1996) *Virology* 219:87-95. Syncytia-mediated loss of CD4<sup>+</sup> cells *in vivo* has been speculated to occur; this could contribute directly to compromise of the immune system, leading to opportunistic infection and full-blown AIDS. Sodrosky *et al.* (1986) *Nature* 322:470-474; Hildreth and Orentas (1989) *Science* 244:1075-1078; Finkel and Banda (1994). Thus critical changes in chimpanzee ICAM-1, ICAM-2 or ICAM-3 may deter syncytia formation in chimpanzee and help explain chimpanzee resistance to AIDS progression. Because of the polyfunctional nature of ICAMs, these positively selected changes in the ICAM genes may additionally confer resistance to other infectious diseases or may play a role in other inflammatory processes that may also be of value in the development of human therapeutics. The polypeptide sequence alignments of ICAM-1, -2, and -3 are shown in Figures 5, 6, and 7, respectively.

**EXAMPLE 6: Characterization of ICAM-1, ICAM-2 and ICAM-3 positively selected sequences**

A sequence identified by the methods of this invention may be further tested and characterized by cell transfection experiments. For example, human cells in culture, when transfected with a chimpanzee polynucleotide identified by the methods described herein (such as ICAM-1 (or ICAM-2 or ICAM-3); see below), could be tested for reduced viral dissemination and/or propagation using standard assays in the art, and compared to control cells. Other indicia may also be measured, depending on the perceived or apparent functional nature of the polynucleotide/polypeptide to be tested. For example, in the case of ICAM-1 (or ICAM-2 or ICAM-3), syncytia formation may be measured and compared to control (untransfected) cells. This would test whether the resistance arises from prevention of syncytia formation in infected cells.

Cells which are useful in characterizing sequences identified by the methods of this invention and their effects on cell-to-cell infection by HIV-1 are human T-cell lines which are permissive for infection with HIV-1, including, *e.g.*, H9 and HUT78 cell lines, which are available from the ATCC.

For cell transfection assays, ICAM-1 (or ICAM-2 or ICAM-3) cDNA (or any cDNA identified by the methods described herein) can be cloned into an appropriate expression

vector. To obtain maximal expression, the cloned ICAM-1 (or ICAM-2 or ICAM-3) coding region is operably linked to a promoter which is active in human T cells, such as, for example, an IL-2 promoter. Alternatively, an ICAM-1 (or ICAM-2 or ICAM-3) cDNA can be placed under transcriptional control of a strong constitutive promoter, or an inducible promoter. Expression systems are well known in the art, as are methods for introducing an expression vector into cells. For example, an expression vector comprising an ICAM-1 (or ICAM-2 or ICAM-3) cDNA can be introduced into cells by DEAE-dextran or by electroporation, or any other known method. The cloned ICAM-1 (or ICAM-2 or ICAM-3) molecule is then expressed on the surface of the cell. Determination of whether an ICAM-1 (or ICAM-2 or ICAM-3) cDNA is expressed on the cell surface can be accomplished using antibody(ies) specific for ICAM-1 (or ICAM-2 or ICAM-3). In the case of chimpanzee ICAM-1 (or ICAM-2 or ICAM-3) expressed on the surface of human T cells, an antibody which distinguishes between chimpanzee and human ICAM-1 (or ICAM-2 or ICAM-3) can be used. This antibody can be labeled with a detectable label, such as a fluorescent dye. Cells expressing chimpanzee ICAM-1 (or ICAM-2 or ICAM-3) on their surfaces can be detected using fluorescence-activated cell sorting and the anti-ICAM-1 (or ICAM-2 or ICAM-3) antibody appropriately labeled, using well-established techniques.

Transfected human cells expressing chimpanzee ICAM-1 (or ICAM-2 or ICAM-3) on their cell surface can then be tested for syncytia formation, and/or for HIV replication, and/or for number of cells infected as an index of cell-to-cell infectivity. The chimpanzee ICAM-1 (or ICAM-2 or ICAM-3)-expressing cells can be infected with HIV-1 at an appropriate dose, for example tissue culture infectious dose 50, *i.e.*, a dose which can infect 50% of the cells. Cells can be plated at a density of about  $5 \times 10^5$  cells/ml in appropriate tissue culture medium, and, after infection, monitored for syncytia formation, and/or viral replication, and/or number of infected cells in comparison to control, uninfected cells. Cells which have not been transfected with chimpanzee ICAM-1 (or ICAM-2 or ICAM-3) also serve as controls. Syncytia formation is generally observed in HIV-1-infected cells (which are not expressing chimpanzee ICAM-1 (or ICAM-2 or ICAM-3)) approximately 10 days post-infection.

To monitor HIV replication, cell supernatants can be assayed for the presence and amount of p24 antigen. Any assay method to detect p24 can be used, including, for



example, an ELISA assay in which rabbit anti-p24 antibodies are used as capture antibody, biotinylated rabbit anti-p24 antibodies serve as detection antibody, and the assay is developed with avidin-horse radish peroxidase. To determine the number of infected cells, any known method, including indirect immunofluorescence methods, can be used. In  
5 indirect immunofluorescence methods, human HIV-positive serum can be used as a source of anti-HIV antibodies to bind to infected cells. The bound antibodies can be detected using FITC-conjugated anti-human IgG, the cells visualized by fluorescence microscopy and counted.

Another method for assessing the role of a molecule such as ICAM-1 (or ICAM-2  
10 or ICAM-3) involves successive infection of cells with HIV. Human cell lines, preferably those that do not express endogenous ICAM (although cell lines that do express endogenous ICAM may also be used), are transfected with either human or chimpanzee ICAM-1 or -2 or -3. In one set of experiments, HIV is collected from the supernatant of HIV-infected human ICAM-1 (or ICAM-2 or ICAM-3)-expressing cells and used to infect  
15 chimpanzee ICAM-1 (or ICAM-2 or ICAM-3)-expressing cells or human ICAM-1 (or ICAM-2 or ICAM-3)-expressing cells. Initial infectivity, measured as described above, of both the chimpanzee ICAM-1 (or ICAM-2 or ICAM-3)- and the human ICAM-1 (or ICAM-2 or ICAM-3)-expressing cells would be expected to be high. After several rounds of replication, cell to cell infectivity would be expected to decrease in the chimpanzee  
20 ICAM-1 (or ICAM-2 or ICAM-3) expressing cells, if chimpanzee ICAM-1 (or ICAM-2 or ICAM-3) confers resistance. In a second set of experiments, HIV is collected from the supernatant of HIV-infected chimpanzee ICAM-1 (or ICAM-2 or ICAM-3)-expressing cells, and used to infect human ICAM-1 (or ICAM-2 or ICAM-3)-expressing cells. In this case, the initial infectivity would be expected to be much lower than in the first set of  
25 experiments, if ICAM-1 (or ICAM-2 or ICAM-3) is involved in susceptibility to HIV progression. After several rounds of replication, the cell to cell infectivity would be expected to increase.

The identified human sequences can be used in establishing a database of candidate human genes that may be involved in conferring, or contributing to, AIDS susceptibility or  
30 resistance. Moreover, the database not only provides an ordered collection of candidate genes, it also provides the precise molecular sequence differences that exist between human

and an AIDS-resistant non-human primate (such as chimpanzee) and thus defines the changes that underlie the functional differences.

**EXAMPLE 7: Molecular Modeling of ICAM-1 and ICAM-3**

5            Modeling of the three-dimensional structure of ICAM-1 and ICAM-3 has provided additional evidence for the role of these proteins in explaining chimpanzee resistance to AIDS progression.

10            In the case of ICAM-1, 5 of the 6 amino acid replacements that are unique to the chimpanzee lineage are immediately adjacent (i.e., physically touching) to those amino acids identified by mutagenic studies as critical to LFA-1 binding. These five amino acid replacements are human L18 to chimp Q18, human K29 to chimp D29, human P45 to chimp G45, human R49 to chimp W49, and human E171 to chimp Q171. This positioning cannot be predicted from the primary structure (i.e., the actual sequence of amino acids). None of the amino acid residues critical for binding has changed in the chimpanzee ICAM-1 protein.

15            Such positioning argues strongly that the chimpanzee ICAM-1 protein's basic function is unchanged between humans and chimpanzees; however, evolution has wrought fine-tuned changes that may help confer upon chimpanzees their resistance to progression of AIDS. The nature of the amino acid replacements is being examined to allow exploitation of the three-dimensional structural information for developing agents for therapeutic intervention. Strikingly, 4 of the 5 chimpanzee residues are adjacent to critical binding residues that have been identified as N-linked glycosylation sites. This suggests that differences exist in binding constants (to LFA-1) for human and chimpanzee ICAM-1. These binding constants are being determined. Should the binding constants prove lower in chimpanzee ICAM-1, it is possible to devise small molecule agents to mimic (by way of steric hindrance) the change in binding constants as a potential therapeutic strategy for HIV-infected humans. Similarly, stronger binding constants, if observed for chimpanzee ICAM-1, will suggest alternative strategies for developing therapeutic interventions for HIV-1 infected humans.

20            In the case of ICAM-3, a critical amino acid residue replacement from proline (observed in seven humans) to glutamine (observed in three chimpanzees) is predicted from

our modeling studies to significantly change the positional angle between domains 2 and 3 of human and chimpanzee ICAM-3. The human protein displays an acute angle at this juncture. Klickstein, *et al.*, 1996 J. Biol. Chem. 27:239 20-27. Loss of this sharp angle (bend) is predicted to render chimpanzee ICAM-3 less easily packaged into HIV-1 virions (In infected humans, after ICAMs are packaged into HIV virions, cell-to-cell infectivity dramatically increases. Barbeau, B. *et al.*, 1998 J. Virol. 72:7125-7136). This failure to easily package chimp ICAM-3 into HIV virions could then prevent the increase in cell-to-cell infectivity seen in infected humans. This would then account for chimpanzee resistance to AIDS progression.

A small molecule therapeutic intervention whereby binding of a suitably-designed small molecule to the human proline residue causes (as a result of steric hindrance) the human ICAM-1 protein to mimic the larger (i.e., less-acute) angle of chimpanzee ICAM-3 is possible. Conservation between the 2 proteins of the critical binding residues (and the general resemblance of immune responses between humans and chimpanzees) argues that alteration of this angle will not compromise the basic function of human ICAM-3. However, the human ICAM-3 protein would be rendered resistant to packaging into HIV virions, thus mimicking (in HIV-1 infected humans) the postulated pathway by which infected chimpanzees resist progression to AIDS.

#### **EXAMPLE 8: Identifying Positive Selection of MIP-1 $\alpha$**

MIP-1 $\alpha$  is a chemokine that has been shown to suppress HIV-1 replication in human cells in vitro (Cocchi, F. *et al.*, 1995 Science 270:1811-1815). The chimpanzee homologue of the human MIP-1 $\alpha$  gene was PCR-amplified and sequenced. Calculation of the  $K_A/K_S$  ratio (2.1,  $P < 0.05$ ) and comparison to the gorilla homologue reveals that the chimpanzee gene has been positively-selected. As for the other genes discussed herein, the nature of the chimpanzee amino acid replacements is being examined to determine how to exploit the chimpanzee protein for therapeutic intervention.

#### **EXAMPLE 9: Identifying Positive Selection of 17- $\beta$ -Hydroxysteroid Dehydrogenase**

Using the methods of the present invention, a chimpanzee gene expressed in brain has been positively-selected ( $K_A/K_S = 1.6$ ) as compared to its human homologue (GenBank Acc. # X87176) has been identified. The human gene, 17- $\beta$  hydroxysteroid dehydrogenase type IV, codes for a protein known to degrade the two most potent estrogens,  $\beta$ -estradiol, and 5-diol (Adamski, J. *et al.* 1995 *Biochem J.* 311:437-443). Estrogen-related cancers (including, for example, breast and prostate cancers) account for some 40% of human cancers. Interestingly, reports in the literature suggest that chimpanzees are resistant to tumorigenesis, especially those that are estrogen-related. This protein may have been positively-selected in chimpanzees to allow more efficient degradation of estrogens, thus conferring upon chimpanzees resistance to such cancers. If so, the specific amino acid replacements observed in the chimpanzee protein may supply important information for therapeutic intervention in human cancers.

#### EXAMPLE 10: cDNA Library Construction

A chimpanzee brain cDNA library is constructed using chimpanzee brain tissue. The chimpanzee brain tissue can be obtained after natural death so that no killing of animal is necessary for this study. In order to increase the chance of obtaining intact mRNAs expressed in brain, however, the brain is obtained as soon as possible after the animal's death. Preferably, the weight and age of the animal are determined prior to death. The brain tissue used for constructing a cDNA library is preferably the whole brain in order to maximize the inclusion of mRNA expressed in the entire brain. Brain tissue is dissected from the animal following standard surgical procedures.

Total RNA is extracted from the brain tissue and the integrity and purity of the RNA are determined according to conventional molecular cloning methods. Poly A+ RNA is selected and used as template for the reverse-transcription of cDNA with oligo (dT) as a primer. The synthesized cDNA is treated and modified for cloning using commercially available kits. Recombinants are then packaged and propagated in a host cell line. Portions of the packaging mixes are amplified and the remainder retained prior to amplification. The library can be normalized and the numbers of independent recombinants in the library is determined.

**EXAMPLE 11: Sequence Comparison**

Randomly selected chimpanzee brain cDNA clones from the cDNA library are sequenced using an automated sequencer, such as the ABI 377. Commonly used primers  
5 on the cloning vector such as the M13 Universal and Reverse primers are used to carry out the sequencing. For inserts that are not completely sequenced by end sequencing, dye-labeled terminators are used to fill in remaining gaps.

The resulting chimpanzee sequences are compared to human sequences via database searches, e.g., BLAST searches. The high scoring "hits," i.e., sequences that show a  
10 significant (e.g., >80%) similarity after BLAST analysis, are retrieved and analyzed. The two homologous sequences are then aligned using the alignment program CLUSTAL V developed by Higgins *et al.* Any sequence divergence, including nucleotide substitution, insertion and deletion, can be detected and recorded by the alignment.

The detected sequence differences are initially checked for accuracy by finding the  
15 points where there are differences between the chimpanzee and human sequences; checking the sequence fluorogram (chromatogram) to determine if the bases that appear unique to human correspond to strong, clear signals specific for the called base; checking the human hits to see if there is more than one human sequence that corresponds to a sequence change; and other methods known in the art as needed. Multiple human sequence entries for the  
20 same gene that have the same nucleotide at a position where there is a different chimpanzee nucleotide provides independent support that the human sequence is accurate, and that the chimpanzee/human difference is real. Such changes are examined using public database information and the genetic code to determine whether these DNA sequence changes result in a change in the amino acid sequence of the encoded protein. The sequences can also be  
25 examined by direct sequencing of the encoded protein.

**EXAMPLE 12: Molecular Evolution Analysis**

The chimpanzee and human sequences under comparison are subjected to  $K_A/K_S$  analysis. In this analysis, publicly available computer programs, such as Li 93 and INA,  
30 are used to determine the number of non-synonymous changes per site ( $K_A$ ) divided by the number of synonymous changes per site ( $K_S$ ) for each sequence under study as described

To further lend support to the significance of a high  $K_A/K_S$  ratio, the sequence under study can be compared in other non-human primates, e.g., gorilla, orangutan, bonobo. These comparisons allow further discrimination as to whether the adaptive evolutionary changes are unique to the human lineage compared to other non-human primates. The sequences can also be examined by direct sequencing of the gene of interest from representatives of several diverse human populations to assess to what degree the sequence is conserved in the human species.

Human brain nucleotide sequences containing evolutionarily significant changes are further characterized in terms of their molecular and genetic properties, as well as their biological functions. The identified coding sequences are used as probe to perform *in situ* mRNA hybridization that reveals the expression pattern of the gene, either or both in terms of what tissues and cell types in which the sequences are expressed, and when they are expressed during the course of development or during cell cycle. Sequences that are expressed in brain may be better candidates as being associated with important human brain functions. Moreover, the putative gene with the identified sequences are subjected to a homologue searching in order to determine what functional classes the sequences belong to.

62

processing, storage and retrieval capabilities, language abilities, as well as others. In this way, this approach provides a new strategy by which such genes can be identified. Lastly, the database not only provides an ordered collection of candidate genes, it also provides the precise molecular sequence differences that exist between human and chimpanzee (and other non-human primates), and thus defines the changes that underlie the functional differences.

In some cases functional differences are evaluated in suitable model systems, including, but not limited to, in vitro analysis such as indicia of long term potentiation (LTP), and use of transgenic animals or other suitable model systems. These will be immediately apparent to those skilled in the art.

#### **EXAMPLE 14: Identification of Positive Selection in a Human Tyrosine Kinase Gene**

Using the methods of the present invention, a human gene (GenBank Acc.# AB014541), expressed in brain has been identified, that has been positively-selected as compared to its chimpanzee homologue. This gene, which codes for a tyrosine kinase, is homologous to a well-characterized mouse gene (GenBank Acc.# AF011908) whose gene product, called AATYK, is known to trigger apoptosis (Gaozza, E. *et al.* 1997 *Oncogene* 15:3127-3135). The literature suggests that this protein controls apoptosis in the developing mouse brain (thus, in effect, "sculpting" the developing brain). The tyrosine kinase domain of this protein is highly conserved between mouse, chimpanzee, and human (as are most tyrosine kinases). Interestingly, however, the region of the protein to which signaling proteins bind has been positively-selected in humans, but strongly conserved in both chimpanzees and mice. The region of the human protein to which signaling proteins bind has not only been positively-selected as a result of point nucleotide mutation, but additionally displays duplication of several SH2 binding domains that exist only as single copies in mouse and chimpanzee. This suggests that a different set of signaling proteins may bind to the human protein, which could then trigger different pathways for apoptosis in the developing human brain compared to those in mice and chimpanzees. Such a gene thus may contribute to unique or enhanced human cognitive abilities.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent to

those of ordinary skill in the art that certain changes and modifications can be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims.



CLAIMSWhat is claimed is:

1. A method for identifying a non-human primate polynucleotide sequence  
5 encoding a polypeptide, wherein said polypeptide may be associated with a physiological  
condition in the non-human primate, comprising the steps of:
  - a. comparing non-human primate protein-coding polynucleotide  
sequences to protein-coding polynucleotide sequences of a human, wherein said human  
does not have the physiological condition; and
  - 10 b. selecting a non-human primate polynucleotide sequence that contains  
a nucleotide change as compared to the corresponding sequence of the human, wherein said  
change is evolutionarily significant.
2. The method of claim 1, wherein the physiological condition is resistance to a  
15 disease.
3. The method of claim 2, wherein the disease is cancer.
4. The method of claim 2, wherein the disease is an infectious disease.  
20
5. The method of claim 4, wherein the infectious disease is a viral disease.
6. The method of claim 5, wherein the viral disease is AIDS.
- 25 7. The method of claim 1, wherein the non-human protein coding sequence is  
associated with development of the physiological condition.
8. The method of claim 1, wherein the non-human primate is a member of the  
hominoid group.  
30

9. The method of claim 8, wherein the non-human primate is selected from the group consisting of chimpanzee, bonobo, gorilla, and orangutan.

10. The method of claim 9, wherein the non-human primate is chimpanzee.

11. The method of claim 1, wherein the nucleotide change is a non-synonymous substitution.

12. The method of claim 1, wherein the evolutionary significance of the nucleotide change is determined according to the non-synonymous substitution rate ( $K_A$ ) of the nucleotide sequence.

13. The method of claim 12, wherein the evolutionary significance of the nucleotide change is determined by the ratio of the non-synonymous substitution rate ( $K_A$ ) to the synonymous rate ( $K_S$ ) of the nucleotide sequence.

14. The method of claim 13, wherein the  $K_A/K_S$  ratio is at least about 0.75.

15. The method of claim 13, wherein the  $K_A/K_S$  ratio is at least about 1.00.

16. The method of claim 13, wherein the  $K_A/K_S$  ratio is at least about 1.25.

17. The method of claim 13, wherein the  $K_A/K_S$  ratio is at least about 1.50.

18. The method of claim 13, wherein the  $K_A/K_S$  ratio is at least about 2.00.

19. A method for identifying a human polynucleotide sequence encoding a polypeptide, wherein said polypeptide may be associated with a physiological condition in the human comprising the steps of:

a. comparing human protein-coding polynucleotide sequences to protein-coding polynucleotide sequences of a non-human primate, wherein said non-human primate does not have the physiological condition; and

b. selecting a human polynucleotide sequence that contains a nucleotide change as compared to the corresponding sequence of the non-human primate, wherein said change is evolutionarily significant.

20. The method of claim 19, wherein the physiological condition is a life span.

21. The method of claim 19, wherein the physiological condition is a brain function.

22. The method of claim 21, wherein the brain function is cognitive function.

23. The method of claim 19, wherein the human protein coding sequence is associated with development of the physiological condition.

24. The method of claim 19, wherein the non-human primate is a member of the hominoid group.

25. The method of claim 24, wherein the non-human primate is selected from the group consisting of chimpanzee, bonobo, gorilla, and orangutan.

26. The method of claim 25, wherein the non-human primate is chimpanzee.

27. The method of claim 19, wherein the nucleotide change is a non-synonymous substitution.

28. The method of claim 19, wherein the evolutionary significance of the nucleotide change is determined according to the non-synonymous substitution rate ( $K_A$ ) of the nucleotide sequence.

29. The method of claim 28, wherein the evolutionary significance of the nucleotide change is determined by the ratio of the non-synonymous substitution rate ( $K_A$ ) to the synonymous rate ( $K_S$ ) of the nucleotide sequence.

5

30. The method of claim 29, wherein the  $K_A/K_S$  ratio is at least about 0.75.

31. The method of claim 29, wherein the  $K_A/K_S$  ratio is at least about 1.00.

10

32. The method of claim 29, wherein the  $K_A/K_S$  ratio is at least about 1.25.

33. The method of claim 29, wherein the  $K_A/K_S$  ratio is at least about 1.50.

34. The method of claim 29, wherein the  $K_A/K_S$  ratio is at least about 2.00.

15

35. The method for identifying an evolutionarily significant change in a human brain protein-coding polynucleotide sequence, comprising the steps of:

a. comparing human brain protein-coding polynucleotide sequences to corresponding sequences of a non-human primate; and

20

b. selecting a human polynucleotide sequence that contains a nucleotide change as compared to corresponding sequence of the non-human primate, wherein said change is evolutionarily significant.

36. The method of claim 35, wherein the non-human primate is a member of the hominoid group.

25

37. The method of claim 36, wherein the non-human primate is selected from the group consisting of chimpanzee, bonobo, gorilla, and orangutan.

30

38. The method of claim 37, wherein the non-human primate is chimpanzee.

39. The method of claim 35, wherein the human brain protein-coding nucleotide sequences correspond to human brain cDNAs.

5 40. The method of claim 35, wherein the nucleotide change is a non-synonymous substitution.

41. The method of claim 35, wherein the evolutionary significance of the nucleotide change is determined according to the non-synonymous substitution rate ( $K_A$ ) of the nucleotide sequence.

10 42. The method of claim 41, wherein the evolutionary significance of the nucleotide change is determined by the ratio of the non-synonymous substitution rate ( $K_A$ ) to the synonymous rate ( $K_S$ ) of the nucleotide sequence.

15 43. The method of claim 42, wherein the  $K_A/K_S$  ratio is at least about 0.75.

44. The method of claim 42, wherein the  $K_A/K_S$  ratio is at least about 1.00.

45. The method of claim 42, wherein the  $K_A/K_S$  ratio is at least about 1.25.

20 46. The method of claim 42, wherein the  $K_A/K_S$  ratio is at least about 1.50.

47. The method of claim 42, wherein the  $K_A/K_S$  ratio is at least about 2.00.

25 48. A method for large-scale sequence comparison between human protein-coding polynucleotide sequences and protein-coding polynucleotide sequences from a non-human primate, comprising:

a. aligning the human polynucleotide sequences with corresponding polynucleotide sequences from a non-human primate according to sequence homology; and

b. identifying any nucleotide changes within the human sequences as compared to the homologous sequences from the non-human primate, wherein the changes are evolutionarily significant.

5           49.    The method of claim 48, wherein the protein coding sequences are from brain.

          50.-   A method of identifying an agent which may modulate a physiological condition, said method comprising contacting at least one agent to be tested with a cell that  
10       has been transfected with a polynucleotide sequence identified in claim 1, wherein an agent is identified by its ability to modulate function of the polynucleotide sequence.

          51.    An agent identified by the method of claim 50.

15           52.    A method of identifying an agent which may modulate a physiological condition, said method comprising contacting at least one agent to be tested with a cell that has been transfected with a polynucleotide sequence identified in claim 19, wherein an agent is identified by its ability to modulate function of the polynucleotide sequence.

20           53.    An agent identified by the method of claim 52.

          54.    A method of identifying an agent which may modulate a physiological condition, said method comprising contacting at least one agent to be tested with a polypeptide encoded within a polynucleotide sequence identified in claim 1, or a  
25       composition comprising said polypeptide, wherein an agent is identified by its ability to modulate function of the polypeptide sequence.

          55.    An agent identified in the method of claim 54.

30           56.    A method of identifying an agent which may modulate a physiological condition, said method comprising contacting at least one agent to be tested with a

polypeptide encoded within a polynucleotide sequence identified in claim 19, or a composition comprising said polypeptide, wherein an agent is identified by its ability to modulate function of the polypeptide sequence.

5           57.    An agent identified in the method of claim 56.

58.    A method for correlating an evolutionarily significant human nucleotide change to a physiological condition in a human, comprising:

10           Analyzing a functional effect, if any, of a polynucleotide sequence identified in claim 1 in a suitable model system, wherein presence of a functional effect indicates a correlation between the evolutionarily significant nucleotide change and the physiological condition.

59.    A method for correlating an evolutionarily significant human nucleotide change to a physiological condition in a human, comprising:

15           Analyzing a functional effect, if any, of a polynucleotide sequence identified in claim 19 in a suitable model system, wherein presence of a functional effect indicates a correlation between the evolutionarily significant nucleotide change and the physiological condition.

20           60.    A method for correlating an evolutionarily significant human nucleotide change to a physiological condition in a human, comprising:

25           Analyzing a functional effect, if any, of a polypeptide encoded in a polynucleotide sequence identified in claim 1 in a suitable model system, wherein presence of a functional effect indicates a correlation between the evolutionarily significant nucleotide change and the physiological condition.

61.    A method for correlating an evolutionarily significant human nucleotide change to a physiological condition in a human, comprising:

30           Analyzing a functional effect, if any, of a polypeptide encoded in a polynucleotide sequence identified in claim 19 in a suitable model system, wherein presence of a

functional effect indicates a correlation between the evolutionarily significant nucleotide change and the physiological condition.

5 62. A method for identifying a target site which may be suitable for therapeutic intervention, comprising comparing a non-human polypeptide encoded in a polynucleotide sequence identified in the method of claim 19 with a corresponding human polypeptide, wherein a location of a molecular difference, if any, indicates a target site.

10 63. A method for identifying a target site which may be suitable for therapeutic intervention, comprising comparing a human polypeptide encoded in a polynucleotide sequence identified in the method of claim 1 with a corresponding non-human polypeptide, wherein a location of a molecular difference, if any, indicates a target site.

15



# PRIMATE PHYLOGENY




FIGURE 1

## FIGURE 2

3/28

1515 ICAM GORILLA

CAG ACA TCT GTG TCC CCC CCA AAA GTC ATC CTG CCC CGG GGA GGC TCC GTG CTG GTG ACA  
TGC AGC ACC TCC TGT GAC CAG CCC ACC TTG TTG GGC ATA GAG ACC CCG TTG CCT AAA AAG  
GAG TTG CTC CTG CTT GGG AAC AAC CAG AAG GTG TAT GAA CTG AGC AAT GTG CAA GAA GAT  
AGC CAA CCA ATG TGT TAT TCA AAC TGC CCT GAT GGG CAG TCA ACA GCT AAA ACC TTC CTC  
ACC GTG TAC TGG ACT CCA GAA CGG GTG GAA CTG GCA CCC CTC CCC TCT TGG CAG CCA GTG  
GGC AAG GAC CTT ACC CTA CGC TGC CAG GTG GAG GGT GGG GCA CCC CGG GCC AAC CTC ATC  
GTG GTG CTG CTC CGT GGG GAG GAG GAG CTG AAA CGG GAG CCA GCT GTG GGG GAG CCC GCC  
GAG GTC ACG ACC ACG GTG CCG GTG GAG AAA GAT CAC CAT GGA GCC AAT TTC TTG TGC CGC  
ACT GAA CTG GAC CTG CGG CCC CAA GGG CTG AAG CTG TTT GAG AAC ACC TCG GCC CCC TAC  
CAG CTC CAA ACC TTT GTC CTG CCA GCG ACT CCC CCA CAA CTT GTC AGC CCT CGG GTC CTA  
GAG GTG GAC ACG CAG GGG ACT GTG GTC TGT TCC CTG GAC GGG CTG TTC CCA GTC TCG GAG  
GCC CAG GTC CAC CTG GCA CTG GGG GAC CAG AGG TTG AAC CCC ACA GTC ACC TAT GGC AAC  
GAC TCC TTC TCA GCC AAG GCC TCA GTC AGT GTG ACC GCA GAG GAC GAG GGC ACC CAG TGG  
CTG ACG TGT GCA GTA ATA CTG GGG ACC CAG AGC CAG GAG ACA CTG CAG ACA GTG ACC ATC  
TAC AGC TTT CCG GCA CCC AAC GTG ATT CTG ACG AAG CCA GAG GTC TCA GAA GGG ACC GAG  
GTG ACA GTG AAG TGT GAG GCC CAC CCT AGA GCC AAG GTG ACA CTG AAT GGG GTT CCA GCC  
CAG CCA CCG GGC CCG AGG ACC CAG TTC CTG CTG AAG GCC ACC CCA GAG GAC AAC GGG CGC  
AGC TTC TCC TGC TCT GCA ACC CTG GAG GTG GCC GGC CAG CTT ATA CAC AAG AAC CAG ACC  
CGG GAG CTT CGT GTC CTG TAT GGC CCC CGA CTG GAT GAG AGG GAT TGT CCG GGA AAC TGG  
ACG TGG CCA GAA AAT TCC CAG CAG ACT CCA ATG TGC CAG GCT TGG GGG AAC CCA TTG CCC  
GAG CTC AAG TGT CTA AAG GAT GGC ACT TTC CCA CTG CCC GTC GGG GAA TCA GTG ACT GTC  
ACT CGA GAT CTT GAG GGC ACC TAC CTC TGT CGG GCC AGG AGC ACT CAA GGG GAG GTC ACC  
CGC GAG GTG ACC GTG AAT GTG CTC TCC CCC CGG TAT GAG TTT GTC ATC ATC GCT GTG GTA  
GCA GCC GCA GTC ATA ATG GGC ACT GCA GGC CTC AGC ACG TAC CTC TAT AAC CGC CAG CGG  
AAG ATC AGG AAA TAC AGA CTA CAA CAG GCT CAA AAA GGG ACC CCC ATG AAA CCG AAC ACA  
CAA GCC ACG CCT CCC

FIGURE 3

1515 ICAM ORANG

CAC ACA TCT GTG TCC TCC GCC AAC GTC TTC CTG CCC CGG GGA GGC TCC GTG CTA GTG AAT  
TGC AGC ACC TCC TGT GAC CAG CCC ACC TTG TTG GGC ATA GAG ACC CCG TTG CCT AAA AAG  
GAG TTG CTC CCG GGT GGG AAC AAC TGG AAG ATG TAT GAA CTG AGC AAT GTG CAA GAA GAT  
AGC CAA CCA ATG TGC TAT TCA AAC TGC CCT GAT GGG CAG TCA GCA GCT AAA ACC TTC CTC  
ACC GTG TAC TGG ACT CCA GAA CGG GTG GAA CTG GCA CCC CTC CCC TCT TGG CAG CCA GTG  
GGC AAG AAC CTT ACC CTA CGC TGC CAG GTG GAG GGT GGG GCA CCC CGG GCC AAC CTC ACC  
GTG GTA TTG CTC CGT GGG GAG GAG GAG CTG AGC CGG CAG CCA GCG GTG GGG GAG CCC GCC  
GAG GTC ACG GCC ACG GTG CTG GCG AGG AAA GAT GAC CAC GGA GCC AAT TTC TCG TGC CGC  
ACT GAA CTG GAC CTG CGG CCC CAA GGG CTG GAG CTG TTT GAG AAC ACC TCG GCC CCC CAC  
CAG CTC CAA ACC TTT GTC CTG CCA GCG ACT CCC CCA CAA CTT GTC AGC CCC CGG GTC CTA  
GAG GTG GAC ACG CAG GGG ACC GTG GTC TGT TCC CTG GAC GGG CTG TTC CCA GTC TCG GAG  
GCC CAG GTC CAC TTG GCA CTG GGG GAC CAG AGG TTG AAC CCC ACA GTC ACC TAT GGC GTC  
GAC TCC CTC TCG GCC AAG GCC TCA GTC AGT GTG ACC GCA GAG GAG GAG GGC ACC CAG TGG  
CTG TGG TGT GCA GTG ATA CTG AGG AAC CAG AGC CAG GAG ACA CGG CAG ACA GTG ACC ATC  
TAC AGC TTT CCT GCA CCC AAC GTG ACT CTG ATG AAG CCA GAG GTC TCA GAA GGG ACC GAG  
GTG ATA GTG AAG TGT GAG GCC CAC CCT GCA GCC AAC GTG ACG CTG AAT GGG GTT CCA GCC  
CAG CCG CCG GGC CCG AGG GCC CAG TTC CTG CTG AAG GCC ACC CCA GAG GAC AAC GGG CGC  
AGC TTC TCC TGC TCT GCA ACC CTG GAG GTG GCC GGC CAG CTT ATA CAC AAG AAC CAG ACC  
CGG GAG CTT CGA GTC CTG TAT GGC CCC CGA CTG GAC GAG AGG GAT TGT CCG GGA AAC TGG  
ACG TGG CCA GAA AAC TCC CAG CAG ACT CCA ATG TGC CAG GCT TGG GGG AAC CCC TTG CCC  
GAG CTC AAG TGT CTA AAG GAT GGC ACT TTC CCA CTG CCC ATC GGG GAA TCA GTG ACT GTC  
ACT CGA GAT CTT GAG GGC ACC TAC CTC TGT CGG GCC AGG AGC ACT CAA GGG GAG GTC ACC  
CGC GAG GTG ACC GTG AAT GTG CTC TCC CCC CGG TAT GAG ATT GTC ATC ATC ACT GTG GTA  
GCA GCC GCA GCC ATA CTG GGC ACT GCA GGC CTC AGC ACG TAC CTC TAT AAC CGC CAG CGG  
AAG ATC AGG ATA TAC AGA CTA CAA CAG GCT CAA AAA GGG ACC CCC ATG AAA CCA AAC ACA  
CAA ACC ACG CCT CCC

FIGURE 4

Human J03132	QTSVSPSKVI	LPRGGSVLVT	CSTSCDQPKL	LGIETPLPKK	ELLLPGNNRK
Human X06990	.....	.....	.....	.....	.....
Human X59286-8	.....	.....	.....	.....	.....
Human #4	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human M24283	.....	.....	.....	.....	.....
Human U86814	.....	.....	.....M	.....	.....
Chimp M86848	.....P	.....Q	.....D	.....	.....G...W
Chimp #1	.....P	.....Q	.....D	.....	.....G...W
Gorilla #1	.....P	.....	.....T	.....	.....L...Q
Gorilla #2	.....P	.....	.....T	.....	.....L...Q
Orang	H....SAN.F	.....N	.....T	.....	.....PG...W
Human J03132	VVELSNVQED	SQPMCSNCP	DGSTAKTFL	TVYWTPERVE	LAPLPSWQPV
Human X06990	.....	.....	.....	.....	.....
Human X59286-8	.....	.....	.....	.....	.....
Human #4	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human M24283	.....	.....	.....	.....	.....
Human U86814	.....	.....	.....	.....	.....
Chimp M86848	.....	.....	.....	.....	.....
Chimp #1	.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....
Orang	M.....	.....	.....A	.....	.....
Human J03132	GKNLTLRCQV	EGGAPRANLT	VLLRGEKEL	KREPAVGEP	EVTTTVLVR
Human X06990	.....	.....	.....	.....	.....
Human X59286-8	.....	.....	.....	.....	.....
Human #4	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....

FIGURE 5(A)

Human M24283	.....	.....	.....	.....	.....
Human U86814	?????????	?????????	?????????	?????????	?????????
Chimp M86848	.D.....	.....	.....	.....	.E.....
Chimp #1	.D.....	.....	.....	.....	.E.....
Gorilla #1	.D.....	.....I	.....E.	.....	.P.EK
Gorilla #2	.D.....	.....I	.....E.	.....	.P.EK
Orang	.....	.....	.....E..	S.Q.....	.A...A.K
Human J03132	DHGFANFSCR	TELDLRPQGL	ELFENTSAPY	QLQTFVLPAT	PPQLVSPRVL
Human X06990	.....	.....	.....	.....	.....
Human X59286-8	.....	.....	.....	.....	.....
Human #4	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human M24283	.....	.....	.....	.....	.....
Human U86814	?????????	?????????	?????????	?????????	?????????
Chimp M86848	.....	:	Q.....H	.....	.....
Chimp #1	.....	.....	Q.....H	.....	.....
Gorilla #1	.....L..	.....	K.....	.....	.....
Gorilla #2	.....L..	.....	K.....	.....	.....
Orang	.D.....	.....	.....H	.....	.....
Human J03132	EVDTQGTVWC	SLDGFLFPVE	AQVHLALGDQ	RLNPTVTYGN	DSFSAKASVS
Human X06990	.....	.....	.....	.....	.....
Human X59286-8	.....	.....	.....	.....	.....
Human #4	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human M24283	.....	.....	.....	.....	.....
Human U86814	?????????	?????????	?????????	?????????	?????????
Chimp M86848	.....	.....L.	.....	.....	.....
Chimp #1	.....	.....L.	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....

**FIGURE 5(B)**

**FIGURE 5(C)**

[illegible]

**FIGURE 5(D)**



Gorilla #1	...F...A..	.....	.....	..R.....	.....
Gorilla #2	...F...A..	.....	.....	..R.....	.....
Orang	.....	...A.L....	.....	..RI.....	.....
Human J03132	QATPP				
Human X06990	.....				
Human X59286-8	.....				
Human #4	.....				
Human #7	.....				
Human #8	.....				
Human M24283	.....				
Human U86814	?????				
Chimp M86848	.....				
Chimp #1	.....				
Gorilla #1	.....				
Gorilla #2	.....				
Orang	.T....				

FIGURE 5(E)

SUBSTITUTE SHEET (RULE 26)

Human M32331	SDEKVFEVHV	RPKKLAVEPK	GSLEVNCSTT	CNQPEVGGLE	TSLDKILLDE
Human #4	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human X15606	.....	.....	.....	.....	..N.....
Chimp #1	.....	.....	..K.....	.....	.....
Chimp #2	.....	.....	..K.....	.....	.....
Gorilla #2	.....	.....	A.....	.....	.....
Human M32331	QAQWKHYLVS	NISHDTVLQC	HFTCSGKQES	MNSNVSVYQP	PROVILTLPQ
Human #4	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human X15606	.....	.....	.....	.....	.....
Chimp #1	.....	.....	.....	.....	.....
Chimp #2	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....
Human M32331	TLVAVGKSFT	IECRVPTVEP	LDSLTLFLFR	GNETLHYETF	GKAAPAPQEA
Human #4	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human X15606	.....	.....	.....	.....	.....
Chimp #1	.....	.....	.....	.....	.....
Chimp #2	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....NQ..	.....L...
Human M32331	TATFNSTADR	EDGHRNFSC	AVLDLMSRGG	NIFHKHSAPK	MLEIYEPVSD
Human #4	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human X15606	.....	.....	.....	.....	.....
Chimp #1	.V.....	D.....	.....	.....	.....
Chimp #2	.V.....	D.....	.....	.....	.....
Gorilla #2	.....	.....	.....I.....	.....QE.....	.....

FIGURE 6 (A)

SUBSTITUTE SHEET (RULE 26)

Human M32331	SOMVIIVTVV	SVLLSLFVTS	VLLCFIFGQH	LRQQRMGTYG	VRAAWRRLLPQ
Human #4	.....	.....	.....	.....	.....
Human #8	.....	.....	.....	.....	.....
Human X15606	.....	.....	.....	.....	.....
Chimp #1	.....	.....	.....	.....	.....
Chimp #2	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....
Human M32331	AFRP				
Human #4	....				
Human #8	....				
Human X15606	....				
Chimp #1	....				
Chimp #2	....				
Gorilla #2	....				

FIGURE 6 (B)

Human X69819	QEFLLRVEPQ	NPVLSAGGSL	FVNCSTDCPS	SEKIALETSL	SKELVASGMG
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	F.....	.....
Chimp #3	.....	.....	.....	.....	.....
Chimp #4	.....	.....	.....	.....	.....
Chimp #5	.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....
Orang	.....	.....	L.....	.....	.....
		P.....		K.....	DN...
Human X69819	WAAFNLSNVT	GNSRIILCSVY	CNGSQITGSS	NITVYGLPER	VELAPLPPWQ
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	.....	.....
Chimp #4	.....	.....	.....	R.....	.....
Chimp #5	.....	.....	.....	R.....	.....
Gorilla #1	.....	.....	.....	R.....	.....
Gorilla #2	.....	.....	.....	R.....	.....
Orang	.....	.....	I.....	R.....	.....
	Y.....	.....			L...
Human X69819	PVGQNFTLRC	QVEGGSPRTS	LTVVLLRWEE	ELSRQPAVEE	PAEVTATVLA
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	Q.....	.....	.....	.....	.....
Chimp #4	Q.....	.....	.....	.....	.....
Chimp #5	R.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	P.....
Gorilla #2	.....	.....	.....	.....	P.....

FIGURE 7 (A)

**FIGURE 7 (B)**

**FIGURE 7 (C)**

**FIGURE 7 (D)**

Human X69819	QEFLLRVEPQ	NPVLSAGGSL	FVNCSTDCPS	SEKIALETSL	SKELVASGMG
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	F.....	.....
Chimp #3	.....	.....	.....	.....	.....
Chimp #4	.....	.....	.....	.....	.....
Chimp #5	.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....
Orang	.....	....P.....	L.....	.....K.....	.....DN...
Human X69819	WAAFNLNVNT	GNSRILCSVY	CNGSQITGSS	NITVYGLPER	VELAPLPPWQ
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	.....R.....	.....
Chimp #4	.....	.....	.....	.....R.....	.....
Chimp #5	.....	.....	.....	.....R.....	.....
Gorilla #1	.....	.....	.....	.....R.....	.....
Gorilla #2	.....	.....	.....	.....K.....	.....
Orang	....Y.....	.....	.....I.....	.....R.....	.....L...
Human X69819	PVGQNFTLRC	QVEGGSPTS	LTVVLLRWEE	ELSRQPAVEE	PAEVTATVLA
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	Q.....	.....	.....	.....	.....
Chimp #4	Q.....	.....	.....	.....	.....
Chimp #5	R.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....P.....
Gorilla #2	.....	.....	.....	.....	.....P.....

FIGURE 7 (E)



**FIGURE 7 (I')**

**FIGURE 7 (G)**

[illegible]

**FIGURE 7 (H)**

Human X69819	QEFLLRVEPQ	NPVLSAGGSL	FVNCSTDCPS	SEKIAETSL	SKELVASGMG
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	F.....	.....
Chimp #4	.....	.....	.....	.....	.....
Chimp #5	.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....
Orang	.....	...P.....	L.....	...K.....	...DN...
Human X69819	WAAFNLNVT	GNSRILCSVY	CNGSQITGSS	NITVYGLPER	VELAPLPWQ
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	...R...	.....
Chimp #4	.....	.....	.....	...K...	.....
Chimp #5	.....	.....	.....	...R...	.....
Gorilla #1	.....	.....	.....	...R...	.....
Gorilla #2	.....	.....	.....	...R...	.....
Orang	...Y.....	.....	...I...	...R...	...L...
Human X69819	PVGQNFTRLRC	QVEGGSPTS	LTVVLLRWEE	ELSRQPAVEE	PAEVTATVLA
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	Q.....	.....	.....	.....	.....
Chimp #4	Q.....	.....	.....	.....	.....
Chimp #5	R.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	...P...
Orang	.....	.....	.....	.....	...P...

FIGURE 7 (I)

SUBSTITUTE SHEET (RULE 26)

**FIGURE 7 (J)**

Species	STVTVSCMAG	ARVQVTLDGV	PAAAPGQPAQ	LQLNATESDD	GRSFFCSATLL
Chimp #4	.....	.....	.....	.....T.	.....P.
Chimp #5	.....	.....	.....	.....T.	.....P.
Gorilla #1	...L.....	.....	.....	...I.....	.....P.
Gorilla #2	...L.....	.....	.....	...I.....	.....P.
Orang	.M.....	Q.....	.....	.....L	.....S.P.
Human X69819	STVTVSCMAG	ARVQVTLDGV	PAAAPGQPAQ	LQLNATESDD	GRSFFCSATLL
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	.....	.....R.
Chimp #4	.....	.....	.....	.....	.....R.
Chimp #5	.....	.....	.....	.....	.....R.
Gorilla #1	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....
Orang	.....	.....	.....	.....	.....
Human X69819	EVDFGEFLHRN	SSVQLRVLYG	PKIDRATCPQ	HLKWKDKTRH	VLQCQARGNP
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	.....T.	.....
Chimp #4	.....	.....	.....	.....T.	.....
Chimp #5	.....	.....	.....	.....T.	.....
Gorilla #1	.....	.....	.....	.....T.	.....
Gorilla #2	.....	.....	.....	.....T.	.....
Orang	.....F...	.....	.....	.....	.....
Human X69819	YPELRCLKEG	SSREVPVGIP	FFVNVTHNGT	YQCQASSRG	KYTLVVVMDI
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....

**FIGURE 7 (K)**

**FIGURE 7 (L)**

Human X69819	QEFLLRVEPQ	NPVLSAGSSL	FVNCSTDCPS	SEKIALETSL	SKELVAGMG
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	F.....	.....
Chimp #3	.....	.....	.....	.....	.....
Chimp #4	.....	.....	.....	.....	.....
Chimp #5	.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....
Orang	.....	.....P.....	L.....	.....K.....	.....DN.....
Human X69819	WAAFNLNVT	GNSRILCSVY	CNGSQITGSS	NITVYGLPER	VELAPLPPWQ
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	.....R.....	.....
Chimp #4	.....	.....	.....	.....R.....	.....
Chimp #5	.....	.....	.....	.....R.....	.....
Gorilla #1	.....	.....	.....	.....R.....	.....
Gorilla #2	.....	.....	.....	.....R.....	.....
Orang	.....Y.....	.....	.....I.....	.....R.....	.....L.....
Human X69819	PVGQNFTLRC	QVEGGSPTS	LTVVLLRWEE	ELSRQPAVEE	PAEVTATVLA
Human #4	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....
Chimp #3	Q.....	.....	.....	.....	.....
Chimp #4	Q.....	.....	.....	.....	.....
Chimp #5	R.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....P.....
Gorilla #2	.....	.....	.....	.....	.....P.....

FIGURE 7 (M)

SUBSTITUTE SHEET (RULE 26)



**FIGURE 7 (N)**

**FIGURE 7 (O)**

Human S50015	.....	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	.....	.....	.....
Chimp #4	.....	.....	.....	.....	.....	.....
Chimp #5	.....	.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....	.....
Orang	H.....	.....	.....	.....	.....	R.....
Human X69819	EAGSSHFPV	FVAVLLTLGV	VTIVLALMYV	FREHQSGSY	HVREESTYLP	
Human #4	.....	.....	.....	.....	.....	.....
Human #5	.....	.....	.....	.....	.....	.....
Human #7	.....	.....	.....	.....	.....	.....
Human S50015	.....	.....	.....	.....	.....	.....
Chimp #3	.....	.....	.....	.....	.....	.....
Chimp #4	.....	.....	.....	.....	.....	.....
Chimp #5	.....	.....	.....	.....	.....	.....
Gorilla #1	.....	.....	.....	.....	.....	.....
Gorilla #2	.....	.....	.....	.....	.....	.....
Orang	...N...L.	.L...V....	.V.V.....	....K...R.	...Q...S..	
Human X69819	ITSMOPTFAM	GEFPSRAE				
Human #4	.....	.....				
Human #5	.....	.....				
Human #7	.....	.....				
Human S50015	.....	.....				
Chimp #3	.....Q..	.....				
Chimp #4	.....Q..	.....				
Chimp #5	.....	.....				
Gorilla #1	.....	.....				
Gorilla #2	.....	.....				
Orang	.....	.....T..				

FIGURE 7 (P)




FIGURE 8

SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b>  <b>C12Q 1/68</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/39006</b>  <b>(43) International Publication Date:</b> 5 August 1999 (05.08.99)
<b>(21) International Application Number:</b> PCT/US99/01964  <b>(22) International Filing Date:</b> 29 January 1999 (29.01.99)  <b>(30) Priority Data:</b> 60/073,263      30 January 1998 (30.01.98)      US  <b>(71) Applicant (for all designated States except US):</b> GENOPLEX, INC. [US/US]; 6840 N. Broadway, Denver, CO 80221 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SIKELA, James, M. [US/US]; 6046 S. Kingston Circle, Englewood, CO 80111 (US). MESSIER, Walter [US/US]; 2418 Bowen Street, Longmont, CO 80501 (US).  <b>(74) Agents:</b> POLIZZI, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 4 November 1999 (04.11.99)
<b>(54) Title:</b> METHODS TO IDENTIFY POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES WHICH MAY BE ASSOCIATED WITH PHYSIOLOGICAL AND MEDICAL CONDITIONS  <b>(57) Abstract</b>  The present invention provides methods for identifying polynucleotide and polypeptide sequences in human and/or non-human primates which may be associated with a physiological condition, such as disease (including susceptibility (human) or resistance (chimpanzee) to development of AIDS). The methods employ comparison of human and non-human primate sequences using statistical methods. Sequences thus identified may be useful as host therapeutic targets and/or in screening assays.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/US 99/01964

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LYN D. ET AL.,: "Conservation of sequences between human and gorilla lineages: ADP-ribosyltransferase(NAD+) pseudogene 1 and neighboring retroposons" GENE, vol. 155, - 1995 pages 241-245, XP002114678 see whole doc. esp. summary	1-3, 8-10, 19, 48
A	BURGER H. ET AL.,: "Molecular evolution of interleukin-3" J. MOL. EVOL., vol. 39, no. 3, - September 1994 (1994-09) pages 255-267, XP002114680 --- -/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 September 1999

Date of mailing of the international search report

22/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/01964

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JAEGER E. ET AL.,: "Structure, diversity, and evolution of the T-cell receptor VB gene repertoire in primates" IMMUNOGENETICS, vol. 40, no. 3, - 1994 pages 184-191, XP002114681 see whole doc. esp. tables -----	
A	MESSIER W. & STEWART C.-B.: "Episodic adaptive evolution of primate lysozymes" NATURE, vol. 385, - 9 January 1997 (1997-01-09) pages 151-154, XP002114682 cited in the application the whole document -----	
A	HERBERT G. & EASTEAL S.: "Relative rates of nuclear DNA evolution in human and old world monkey lineages" MOL. BIOL. EVOL., vol. 13, no. 7, - September 1996 (1996-09) pages 1054-1057, XP002114698 the whole document -----	
X,P	LEE M.E. ET AL.,: "Molecular cloning and expression of rhesus macaque and sooty mangabey interleukin 16: biologic activity and effect on simian immunodeficiency virus infection and/or replication" AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14, no. 15, - 15 October 1998 (1998-10-15) pages 1323-1328, XP002114679 the whole document -----	1,2,4-8, 48